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Abstract 
 
 
The World Health Organization (WHO), the National Institutes of Health, and 
UNESCO have stressed the need for a new generation of low-cost vaccines to 
promote vaccination programs in the poorest regions of the world. They especially 
emphasized the need for heat-stable vaccines to avoid the considerable expense in 
maintaining the cold-chain during production and distribution and needle-free 
formulations to eliminate the risk of opportunistic contamination as well as the need 
for qualified personnel.  Influenza is one of the most significant diseases worldwide, 
being implicated in 4 major pandemics and the causative agent of ongoing yearly 
epidemics.  Every year, Influenza A viruses initiate outbreaks of respiratory tract 
infection resulting in unacceptable mortality, especially in immuno-compromised 
persons and the +65's, and morbidity that impact significantly in workplace 
economies.  
 
Influenza H1N1 nucleoprotein (NP) sequence, codon-optimized for C. 
reinhardtii chloroplast-specific regulatory sequences was designed as an epitope to 
induce immunity against influenza. Wild type C. reinhardtii chloroplast genomes were 
transformed by NP transgene expressed under control of chloroplast-specific 
regulatory sequences, promoters and terminators. A large region of the tscA gene 
was used for integration into the chlotroplast genome via homological recombination. 
Integration and expression of NP epitope containing transgene in C. reinhardtii 
chloroplast genomes was confirmed phenotypically by antibiotic spectinomycin 
selection and using a set of molecular biology techniques such as PCR, RT PCR, 
DNA sequencing and ELISA. It is considered further research would be 
advantageous to confirm vaccine candidacy. 
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1.1. Influenza, the virus 
 
Influenza is one of the most significant diseases worldwide, being implicated in 
4 major pandemics and the causative agent of ongoing yearly epidemics. Every year, 
Influenza A viruses initiate outbreaks of respiratory tract infection resulting in 
unacceptable mortality, especially in immunocompromised persons and the +65's, 
and morbidity that impact significantly in workplace economies (Jefferson et al., 
2005; Myers et al., 2007; Restivo et al, 2017; Thomas and Noppenberger, 2007). 
 
 There are 3 Influenza types, A, B, and C, all belonging to the 
Orthomyxoviridae family, the virus types differ genetically depending on their 
adaptability to their hosts and their geographical location.  Of the 3 Influenza viruses, 
Influenza A virus has dominated the animal kingdom, associated mainly with birds, 
humans, horses, pigs and to a lessor extent, dogs, cats and other mammals (Baigent 
and McCauley, 2003; Blazeiewska et al., 2011; Hamilton et al., 2013; Itoa and 
Kawaoka, 2000; Srivastava et al., 2009; Trammell et al., 2012; Torremorell et al., 
2012; van Oirschot, 2001: Vincent et al., 2009).  
 
Avian Influenza (AIV) is the most studied of the Influenza type A viruses and 
includes the highly pathogenic avian influenza H5N1(HPAI H5N1) that is of 
immediate concern with its zooNotIc pandemic potential (Capua and Alexander, 
2004; Korteweg and Gu, 2008; Ligon, 2005; Ma et al., 2010; Suarerz, 2000).  Avian 
Influenza subtypes are defined on the basis of the antigenicity of the haemagglutinin 
and neuraminidase surface proteins, currently the major targets for vaccine and 
antiviral dugs. The haemagglutinin protein allows the virus to attach to the surface of 
a susceptible cell, while the neuraminidase protein allows the virus to be released 
from the infected cell after infection. Sixteen subtypes of haemagglutinin (H1– H16) 
and nine subtypes of neuraminidase (N1–N9) have been described (Fouchier et al., 
2005; MacKellar, 2007).  
 
With reference to human Influenza, the haemagglutinins H1, H2 and H3, and 
neuraminidases N1 and N2 circulate continuously; H5, H7 and H9 have also been 
observed although in these instances humans were incidental targets, all types 
however sharing a common avian origin (Fouchier et al., 2005).  Two further  
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Figure 1.1. Influenza A virus image, electron-microscope.  
HA, NA surface structures are clearly evident.   
Source, Kansas State University and Havard medical school,  
Havard University. 
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haemagglutinin's have also been identified, H17 and H18, though these are 
associated with another animal species, bats. (Tong et al., 2012). 
 
The haemagglutinin and neuraminidase proteins are but 2 of 12 proteins that 
are encoded for from the 8-segmented negative sense single stranded AIV RNA 
genomes.   The remaining 10 proteins include; the ion-channel M2 and envelope M1 
proteins, the internal proteins NS1 and NS2, and the polymerase complex, NP, PB1, 
PB2, PA, as well, PB1-F2 (McCauley and Mahy, 1983). 
 
 1.1.1. Influenza and wild birds 
 
AIV subtype diversity is greatest in wild birds where all 16 haemagglutinins 
and 9 neuraminidases have been isolated. There are many genotypes of AIV, 
varying geographically and between years, as well, between species and populations 
of birds.  The bird populations include, ducks, geese, waterfowl, seabirds and 
domestic poultry (Alexander, 2007; Costa et al., 2010; Chen et al., 2005; Fouchier et 
al., 2005; Haynes et al., 2009; Munster and Fouchier, 2009).  AIV appears to be 
endemic in wild bird populations where the virus/host co-exist with minor to no effects 
to the host, the AIV in this relationship is referred to as LPAIV or of low pathogenicity 
(Alexander, 2000; Krauss et al., 2007; Collisson, 2008; Munster et al., 2005).  
However, when the virus crosses the species barrier, moreso from wild bird 
populations to domesticated birds, in some instances, genetic changes take place in 
the AIV to evolve to HPAIV, high pathogenicity, the HPAIV variant can bring about 
significant morbidity and mortality, (Capua and Marangon, 2006; Daszak et al., 2007; 
Ellis and Bousfield, 2004; Gilbert et al., 2012; Kuchipudi et al., 2009).   
 
The role of wild birds in the dispersal of AIV has been well established for many 
years, that they are the central element of the AIV ecology (Huang et al., 2013; 
Munster and Fouchier, 2009 et al., 2009; Tollis and Di Tani, 2002; Vandegrift et al., 
2010).  Every year worldwide many subtypes of AIV circulate among wild birds and 
have been found in at least 12 orders of birds (Kandeil et al., 2017; Krauss et al., 
2004, Olsen and Munster, 2006; Van der Berg et al., 2008).  Vaccination of wild bird 
populations has long been considered ineffectual (Swayne et al., 2013). 
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 1.1.2. Influenza and domesticated birds,   
   poultry 
 
 The Influenza zooNotIc effect of poultry has been demonstrated repeatedly 
(Cattoli et al., 2011; Ellis and Bousfield, 2004) where poultry is a logical intermediary, 
the 'mixing vessel', for adaptation of AIV strains from wild birds to humans and 
numerous other mammalian species (Pantin-Jackwood et al., 2014; Hamilton et al., 
2009; Webby et al., 2000). 
 
The AIV adaption to new hosts is largely constrained by the respiratory 
epithelial attachment sites presented by the new host where AIV has a preference for 
the sialic α 2,3 Gal receptors, similar to that presented by the original host, wild birds 
(Yamada et al., 2006; de Geus et al., 2012).  Some domestic birds however e.g. 
poultry, have both sialic α 2,3 Gal and sialic α 2,6 Gal receptors, the latter attachment 
sites typically found in mammals, hence the 'mixing vessel' term.  The AIV, through 
adaption to the poultry sialic α 2,6 Gal receptors, mammal species can then become 
infected i.e. humans (Pillai and Lee, 2010; Suzuki et al., 2000; Van Riel et al., 2007).  
 
Depending on the virulence of AIV, AIV strains found in poultry are also 
classified as either low pathogenic (LP) or highly pathogenic (HP) where infection of 
either is considered to being derived from contact with wild bird populations (de Wit 
et al., 2004; Park et al., 2011; Xu et al., 1996). 
 
LPAIV strains cause asymptomatic to mild respiratory and enteric tract 
infections while HPAIV cause clinical illness and systemic infections (Kapczynski et 
al., 2011; Xiu et al., 2011).  Infections of poultry, especially with the HPAIV, results in 
severe economic losses where flock mortality can reach up to 100% in affected 
populations, a devastating impact. LPAIV has a lesser though variable impact, 
depending on the strain and health status of the birds, also, has the potential to 
evolve into HPAIV, for example, the recent HPAIV H7N3 outbreak in Jalisco, Mexico 
(Kapczynski et al., 2013; Cattoli, Fusaro et al., 2011; Burns et al., 2013; Beato et al., 
2009; Wainwright et al., 2012).  
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Figure 1.2. Diagrammatic structure of key Influenza virus proteins. 
 Source, Viralzone, Swiss Institute of Bioinformatics. 
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A number of AIV strains are well established in poultry, mainly; H1, H3, H7 and 
H9, with well documented outbreaks associated with all of these types.  In USA, turkey 
breeders stock, with H1N1, H1N2 and H3N2 swine influenza (Lu et al., 2004).  In Italy, 
poultry layers and turkeys with LPAIV H7N1 and H7N3 LPA (Capua and Alexander, 
2006).  In Middle east and Asia, poultry layers and broilers, with H9N2 (Nill and Asai, 
2002; Vergne et al., 2012); In Korea, ducks, poultry, with H7N7 (Kwon et al., 2005). 
 
   1.1.2.1. Preventative measures 
 
Early detection of HPAIV and LPAIV is essential for implementing effective 
control measures, the control measures include culling of infected flocks and high 
risk contacts, disinfection, biosecurity and introducing effective trade measures and 
vaccination (WHO, 2014; Peiris and Yen, 2014).   Five outbreaks of HPAIV H7 were 
successfully controlled in Australia using these procedures (Hamilton et al., 2009).  
However, delays in detection lead to spiraling cost escalation to keep epidemics 
under control and make the disease more difficult to eradicate (Pasquini-Descomps 
et al, 2017).  In the case of H5N1 HPAIV, early detection and effective control at the 
source is critical to reduce the public health risk (Delwart et al., 2012; Desmettre, 
2011).  
 
The control measures together with consequential cost of control and trade 
measures to minimize further spread, leads to huge economic costs at both local and 
national levels. There is often a greater impact on countries with a lower Gross 
Domestic Product (GDP), who rely on agriculture for economic development and for 
sustenance, as with Thailand, Vietnam and Cambodia.  All being countries who do 
not always have the resources to maintain the infrastructure and technical capacities 
needed for rapid accurate early detection and characterization of viral strains, the 
diagnostic capacity being a much-needed capability to aid the control of the spread of 
outbreaks.  Vaccines have been used in AIV control programs to prevent, manage 
and eradicate AIV from poultry and other domestic birds, where the accepted norm 
for protection is produced from the humoral immune responses against the 
hemagglutinin protein (Gao et al., 2006; Haghighi et al., 2009; Manceur et al., 2017).  
A variety of vaccines have been developed and tested under experimental conditions 
with a few receiving a license for field use following demonstration of purity, safety,  
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 Figure 1.3. The spread of Influenza virus from  
 birds and animals to man. Source, Agence  
 France-Presse image 290409. 
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efficacy and potency (Spackman and Swayne, 2013).  Current licensed vaccines are 
predominately adjuvanted inactivated whole AIV vaccines, they are typically 
produced from low pathogenicity AIV strains or occasionally from high pathogenicity 
AIV strains.  Interestingly, during 2002-2010 an estimated 15 billion vaccines were 
used worldwide, 90% in China, 5% in Egypt, 4% in Asia and 1% the rest of the world 
(Swayne, 2009; Swayne et al., 2013). 
 
Other licensed AIV vaccines include recombinant fowl poxvirus vector with an 
AIV H5 insert and a recombinant Newcastle disease virus vector with an AIV H5 
gene insert, the latter vaccine can be mass administered via aerosol application 
(Park et al., 2006; Qiao et al., 2003; Veits et al., 2006).  In China, an extensive 
vaccination program occurred using mostly inactivated H5, but also recombinant fowl 
poxvirus and recombinant Newcastle disease virus with AIV H5 gene inserts (Qiao et 
al., 2003; Qiao et al., 2008).  Recently, reverse genetic procedures have been 
developed that allow construction of vaccine strains using a genetically altered HA 
gene (changing HP HA proteolytic cleavage site to LP) and a backbone of internal 
gene segments for safe, high growth production (Nang et al., 2013).  
 
Although In-ovo vaccination is widely used other directions are under 
investigation (Manini, 2017).  Vaccine application for mass vaccination is more 
effective by the mucosal route since it induces both local and systemic responses to 
halt infection already at the main portal of entry (de Geusa et al., 2012).  As well, 
changes have made to the makeup of Inactivated vaccines with the inclusion of 
immunogenic adjuvants to enhance immunogenicity since inactivated AIV on its own 
is poorly immunogenic (Van de Berg et al., 2008).  Successful vaccination strategies 
are based around rapid intervention (e.g. emergency vaccination of poultry in the 
area around an outbreak), preventive vaccination of specific categories of poultry that 
are more at risk should a new introduction of AIV occur (e.g. free-range layers in 
areas with many wild ducks and geese) and general preventive vaccinations of 
poultry in area’s in which AIV is endemic (Peiris and Yen, 2014).  The effectiveness 
of mass evacuations however has often been plagued with reports of limited success 
where the vaccine used tended to add to the AIV genetic variation, as well, 
effectiveness compounded by the organizational difficulties in being able to include 
all commercial flocks and backyard flocks (Burns et al., 2013; Hamilton et al., 2013).  
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A vaccine is needed for the domesticated bird/poultry industries that is simple 
in its design, broad in its specificity and cheap to produce.  It is towards meeting 
these 3 endpoints this project was directed. 
 
1.2. Immune responses 
 
 1.2.1. Humoral immunity 
 
Humoral immunity refers to antibody-mediated immune responses. Antibodies 
are produced by plasma cells that protect the host from infection in three main ways: 
by binding to pathogens to inhibit their toxic effects or infectivity (neutralization), by 
coating pathogens and facilitating their uptake and killing by phagocytes 
(opsonization) and by activating the complement cascade. 
   
Currently, two main countermeasures are used to stimulate humoral immunity 
to elicit a response.  
   
1.2.1.1 Vaccination  
A vaccine that is able to stimulate a robust, humoral neutralizing antibody 
response has always been considered the main defence against IAV infection and is 
one of the main criteria to determine vaccine efficacy.  Vaccine design traditionally 
then has been more directed towards the surface viral glycoproteins, in particular 
hemagglutinin (Dormitzer et al., 2011; Hughes et al., 2011; Kang et al., 2009, 2014; 
Kauer et al., 2011; Kilbourne, 2011; Makarkov et al, 2017; Nichol et al., 1995; Wong 
et al., 2013) and of recent times towards universal vaccine development (Crowe, 
2017). 
 
Although cold adapted 'live' attenuated vaccines are regarded as having a 
'gold-star' status since they elicit both humoral and CT (T-cell lymphocyte) 
responses, there are few effective and relatively safe 'live' vaccines available (Girard 
et al., 2010).  Vaccines traditionally have mostly been based on inactivated IAV and 
subunit IAV, designed where possible to closely match the circulating IAV strains 
(Broadbent and Subbarao, 2011; Wu et al, 2017).  However, seasonal influenza 
viruses continuously accumulate amino acid substitutions in the antigenic sites of the 
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HA molecules, this ability is referred to as 'antigenic drift' (Retamal et al, 2017).  
Consequently, due to antigenic drift the circulating influenza viruses are able to 
escape from the neutralizing activity of antibodies induced by previous infections or 
vaccination.  This antigenic variability necessitating continuous vaccine updates, 
provided by surveillance data of circulating IAV strains and genetic relatedness, to 
match the circulating epidemic strains (Boon et al., 2009; Bouvier and Lowen, 2010).  
Predicting which IAV strain will dominate annually is difficult, where mismatches 
between the vaccine and circulating viruses lead to little or no protective effect 
(Duvvuri et al., 2009; Orsi et al, 2017).  As well, through 'antigenic shift', new IAV 
strains circulate with HA molecules that are antigenetically distinct from seasonal 
influenza A viruses that seasonal influenza vaccines are not protective against 
(Huang et al, 2017).  In 1997-1998 a drifted strain caused severe outbreaks because 
it matched poorly with the same year’s vaccine antigens, similarly, in 2003-2004 the 
H3 component drifted from the predicted to match very poorly with the vaccine, the 
efficacy of IAV vaccination decreasing dramatically due to the mismatching.  The 
pandemic of 2009 caused by influenza A/H1N1 viruses of a past swine lineage 
highlighted the matching of a vaccine to the circulating strain is a time-consuming 
process, and, in many countries, vaccines became available after the peak of 
pandemic (Forgie et al., 2011). 
 
1.2.1.2 Antivirals  
These are small-molecule inhibitors of the neuraminidase surface glycoprotein 
and the viral ion channel M2.  They have been widely used and proven to be quite 
effective against susceptible IAV strains (Moscona, A, 2005).  However, resistance to 
these antivirals has reduced their effectiveness, where IAV resistant mutations 
associated with Oseltamivir and Amantadine tbreatments are widespread (Cooper et 
al., 2003). There were numerous cases in the 2009 pH1N1 where Oseltamivir 
resistance were reported (Cooper et al., 2010; Monto et al., 2006). 
 
1.2.2 Cellular immunity 
 
There is considerable interest in the development of more broadly protective 
influenza vaccines that ideally would afford protection against a variety of subtypes of 
influenza A viruses and/or antigenic drift variants within a subtype.  Much of this 
interest is focused on stimulating the cytotoxic T-cell lymphocyte responses (CTL), in  
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Figure 1.4. A diagram of influenza viral cell invasion  
and replication. Source, WikiMedia. Author YK Times 
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particular the CD8+ and CD4+ pathways (Crowe et al., 2006; de Wolf et al., 2017; 
Weber et al., 2009; Webby et al., 2003). 
 
For over thirty years it has been known that infection with influenza A virus can 
induce a certain degree of protective immunity to infection by other influenza A 
viruses of unrelated subtypes (heterosubtypic immunity). There is evidence to show 
that virus-specific CTL's contribute to protective immunity against influenza virus 
infections.  The CTL's target the more conserved virus proteins, since the majority of 
virus-specific T-cells, in particular CD8+ CTLs, are directed against the relatively 
conserved viral proteins like nucleoprotein (NP), matrix 1 protein (M1) and the ion 
channel (M2) (Hillaire et al., 2011; Stanekova and Vareckova, 2010; Webby et al., 
2003).  
 
Because of their cross-reactive nature, virus-specific CTLs offer protection 
against influenza A viruses of various subtypes since several studies have shown 
that post infection serum does not afford protection against heterosubtypic strains, 
whereas virus-specific T cells do (Alexander et al., 2010; deGroot et al., 2009; 
deGroot et al., 2014; Zhong et al., 2003).   
 
Should a novel pandemic IAV strain emerge, the seasonal vaccines will be 
poorly protective, and novel pandemic vaccines will need to be produced which has 
been shown to be a time-consuming process (Gauthier-Clerc and Lebarbenchon, 
2007; Wang et al., 2007).  Under these circumstances the stimulation of a cross-
reactive CTL response although may not prevent infection but could contribute to 
more rapid clearance of infection and so reduce disease severity and mortality. 
 
In serologically naive humans, a robust CTL response is crucial for early 
clearance of the AIV (Wang et al., 2007).  Although CTLs are believed to clear the 
virus mainly through CD8+ T-cell granule-mediated cytotoxicity (Henmann et al., 
2013), CD4+ T-cells are important in the subsequent generation and maintenance of 
memory T-cells (Singh et al., 2010; Singh et al., 2010).  
 
The current rationale for using CTL vaccines is to provide baseline immunity in 
the population that may provide protective against a newly emerging pandemic virus 
(Lim et al., 2013; Shaw, 2012).  While CTL immunity on its own is unlikely to prevent 
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infection and perhaps disease, it could substantially reduce mortality (Boesteanu et 
al., 2010).  In an AIV pandemic scenario, vaccines that induce cross-protective CTL 
could be used for immediate vaccination until vaccines become available that induce 
antibodies of the proper specificity, especially for the immunogenetically impaired 
and naive (de Groot et al., 2014).  
 
A key issue with CTL vaccines, however, is that they need to incorporate an 
epitope that can be recognized universally by all major histocompatibility complex 
(MHC) subclasses (Bui et al., 2007; Tu et al., 2010).  
 
However, it has been shown that although epitope recognition does vary 
across individuals, it is possible to identify epitope regions that are recognized by all 
6 HLA supertypes, such that all highly conserved epitopes in the M1, NP, and PB1 
proteins from more than 17 strains across 6 different subtypes can be targeted by 
CD4+ and CD8+ T cells (Ben-Yedidia and Arnon, 2005; Berthoud et al. 2011; Lillie et 
al., 2012; Liu et al., 2013; Powell et al., 2013).   Another factor that can affect the 
performance of CTL vaccines is epitope immunodominance, in which the CTL 
response is focused on one or a select few epitopes (Tan et al., 2011).  
 
CTLs recognize epitopes in a hierarchical manner that is dependent on many 
factors (Berkhoff et al., 2005).  If the CTL vaccine epitope is immunodominant, it is 
likely to reduce the breadth of response in vaccinated individuals.  The choice of 
epitope can also alter the outcome of the response, depending on the binding avidity 
of the T-cell antigen receptors (TCRs) with the MHC peptide (Valitutti et al., 1995).  
The mode of delivery for CTL-based vaccines must also be considered. To induce a 
strong CD8+ T-cell response, the antigen must be processed through the MHC class 
I processing pathway of dendritic cells (DCs; Tan et al., 2011).  During infection, the 
viral antigen is loaded onto DCs by direct entry of the virus or through uptake of 
infected cells undergoing apoptosis (Albert et al., 1998).  Hence, CTL responses 
during vaccination differ: Live attenuated Influenza vaccine (LAIV) induces a strong 
CD8+ T-cell response, whereas the conventional subunit TIV is less effective than 
the whole-virus vaccine at inducing CTLs (Lanthier et al., 2011).  A number of  
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Figure 1.5. The humoral and cell-mediated immune response to influenza 
virus infection. The humoral branch of the immune system comprises B-
lymphocytes (left), which after interaction with influenza differentiate into antibody-
secreting plasma cells. The cellular response (right) starts with antigen presentation 
via MHC I (black) and II (blue) molecules by dendritic cells, which then leads to 
activation, proliferation and differentiation of antigen-specific T cells (CD4 or CD8). 
These cells gain effector cell function to either help directly, release cytokines, or 
mediate cytotoxicity following recognition of antigen (Adapted from Flint 2004). 
Source, Pathogenesis and Immunology, G Hehrens and M Stoll. 
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vaccines incorporating multi-epitopes have been developed including NP, M1 and M2 
(Stoloff and Caparros-Wanderley, 2007; Pleguezuelos et al., 2012) and another 
multi-epitope approach based on a nanoparticle platform is now undergoing clinical 
trials (Gilbert, 2013).  Therefore, the design and execution of a successful CTL-based 
vaccination approach are crucial and should incorporate all of these considerations.  
 
To date, most CTL vaccines are currently designed to target conserved T-cell 
epitopes in the NP, M1 and M2 proteins, two CTL vaccines have already reached 
clinical testing in humans (Hillaire et al., 2011).  Preliminary data from a phase II trial 
based on a vaccinia virus-vectored (poxvirus) vaccine suggest higher levels of 
stimulation of T-cell responses and protection in vaccines than in the control group 
(Berthoud et al., 2011).  
 
This study pursued the CTL direction, since there is a strong association of 
AIV CTL immune response with rapid clearance, reduction in severity and mortality 
together with the potential of long lasting immunity.   Achieving these endpoints 
would provide optimal protection to the domesticated bird/poultry community.  
 
1.3. Analysis of NP DNA and protein sequences  
 
The predictive epitope bioinformatic tools such as IEDB, RANK, SYFPEITHI 
and EpiMax are important in providing identification of individual epitopes within each 
IAV protein to develop peptide vaccines (de Groot et al., 2010; Martin, 2003; 
Gorbalenya et al., 2010).  The peptide epitopes represent the minimal immunogenic 
region of a protein antigen and allow for precise direction of immune responses 
(Salimi et al., 2010; Parida et al., 2007).  A peptide vaccine should ideally include 
epitopes recognized both by B and T cells and must also take into account the MHC 
restriction of the T-cell response (Rapin et al., 2010).  Although B-cells mainly induce 
antibody production, T-cells induce cellular and cytokine secretion, in some cases B 
and T-cell epitopes can overlap substantially within the sequence of an antigen and 
in others they might be present in separate discrete regions of the antigen or present 
in different antigens from the targeted pathogen.  
 
Synthetic peptides offer distinct advantages over other types of vaccines, 
importantly, the simplicity of producing peptides allows swift changes in the design of 
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peptide vaccines which is a great advantage for the development of vaccines against 
the rapidly changing IAV (Bright et al., 2007; Jeon and Ben-Yedidia, 2002; Wang et 
al., 2011).  As well, their ease of storage, transport and distribution, since peptides 
can be stored freeze-dried, avoiding the need to maintain a “cold chain”, and their 
ease of characterization simplifies the demands of stringent vaccine quality control 
and ultimate approval by the regulatory authorities (Ichihashi et al., 2011; Toussaint 
et al., 2011; Ben-Yedidra and Arnon, 1998).  In addition, the use of synthetic peptides 
provides an alternative for proteins that are currently difficult to produce by 
recombinant technology due to their inherent toxicity (Kaewpongsri et al., 2010).  
 
Despite the potential advantages of this approach, the development of 
successful peptide vaccines has been limited mainly by difficulties associated with 
stability, poor immunogenicity of simple peptides and by the MHC polymorphism of 
the host species (Ichihashi et al., 2011).  Since induction of strong immune 
responses requires a sustained presentation of antigen in a stimulatory context, 
biodegradation of peptides by extracellular proteases does occur. Minimising 
biodegradation can be achieved by synthesis of peptides with translational 
modifications and/or by introducing protease-resistant peptide bonds to stabilize 
these compounds in vivo (Li et al., 2014).  
 
Recent advances on the understanding of the requirements for induction and 
maintenance of efficient immune responses, as well as about the pharmacokinetics 
of peptides, have provided new strategies to enhance both peptide immunogenicity 
and stability, thus returning peptide vaccines to the forefront of vaccine design (Lee 
et al., 2014).  Most of these renewed efforts concentrated on the two major antigens 
involved in protective immunity, namely, the surface structure haemagglutinin and the 
internal nucleoprotein (Gilbert, 2012). 
 
Several peptide vaccines for human use are currently at various stages of 
development, launched by companies as Pfizer, Novartis or Sanofi Pasteur. Different 
strategies have been adopted to enhance the effectiveness of peptide vaccines 
include the use of particulate delivery systems such as ISCOMs, liposomes, VLPs, 
covalent or non-covalent attachment of peptides to proteins that target the 
immunogens, to antigen-presenting cells and the use of recombinant cytokines as 
adjuvants in peptide formulations (Ischihashi et al., 2011).  One of the strategies 
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used to overcome restrictions due to MHC recognition includes multiple epitopes (Li 
et al., 2014).  
 
 1.3.1 Haemagglutinin (HA) epitopes 
 
HA is synthesized initially as an immature polypeptide chain called HA0, which 
is activated upon cleavage by host cell proteases to yield two subunits, HA1 and 
HA2.  The HA1 “head” subunit of HA mediates attachment of the virus to target cells 
through interactions with sialic acid receptors (Shulman, 2009).  After endocytosis by 
the virus, the low pH inside the cell triggers conformational changes in HA2, leading 
to fusion of the viral and endosomal membranes and release of the viral genome into 
the cytoplasm.  Most neutralizing antibodies bind to the exposed loops that surround 
the receptor binding site, HA1, and interfere with viral attachment (Alexander et al., 
2010; Chun et al., 2008).  Because these loops are highly variable, antibodies 
targeting these regions are strain-specific, explaining why immunity after natural 
exposure or vaccination is typically restricted to the current circulating strains (Bright  
et al., 2008).  
 
Recently, antibodies have been identified specific for epitopes located in the 
HA1/HA2 joining region and stalk domain of the HA molecule, displaying broad 
reactivity and broad neutralizing activity against several different influenza A viruses 
of different HA subtypes (Ekiert et al., 20011; Krammer et al., 2013; Margine et al., 
2013; Steel et al., 2010).  Studies targeting epitopes in the highly-conserved stalk 
domain of the HA have come up with divergent findings some citing the domain is 
very promising, for the cross-protection offered, and others report the domain is 
limited and lowly immunogenic (Moise et al., 2013; Huang et al 2013; Sangster et al., 
2013).  
 
 1.3.2 Neuraminidase (NA) epitopes 
 
NA is the second major surface protein of AIV, the function of the NA protein is 
to exert sialolytic enzymatic activity, thus allowing virus particles to become free from 
the host cell receptors releasing new virions from the cell (Ahn and Son, 2012).  The 
NA antibody prevents the release of virus from infected cells (Sylte and Suarez, 
2009) and increases overall resistance to IAV infection.  
 
Influenza nucleoprotein expression in microalgae, B. Cooke 
19 
Some interesting bioinformatics studies have been completed exploring 
publicly available NA sequences, and found common highly conserved NA regions in 
almost all influenza A and B virus that would be a good basis for a common vaccine 
(Liang et al., 2012; Doyle et al., 2013; Huang et al., 2013; Moise et al., 2013; Russell 
et al., 2006). 
 
A common problem with inactivated trivalent vaccine design has been the 
mismatching of NA with circulating strains.  There have been circumstances when 
approved seasonal vaccine strains were poorly matched to the NA antigen (Marcelin 
et al., 2012). 
 
 1.3.3 Matrix (M1 and M2) epitopes 
 
In the study by Heiny (2007), numerous M1 sequences were found to be 
completely conserved in at least 95% of the Influenza avian and human isolates 
despite the major evolutionary variability of the viruses.  The M1 protein featured, 
along with NP and the Influenza polymerases, as the most conserved.  
 
These isotope sequences have been used in numerous studies involving T-
cell responses.  One such study (Tu et al., 2010) concluded one such sequence was 
shown to provide cross-protection in particular to the 2008 pH1N1 epidemic, where, 
had the sequence been included in the vaccine there would have been a lessening of 
the severity of the disease in the community.  This same M1 epitope was used 
successfully in the Vaccinia vectored NP, M1 vaccine that is now in Stage II trials 
(Berthoud et al., 2011). 
 
The most explored universal influenza vaccine target is the extracellular 
domain of the M2 protein (M2e).  M2e has a number of interesting traits, including 
being highly conserved among Influenza A virus subtypes (99%) and its linear 
peptide nature (Ma et al., 2013; Wu et al., 2007).  M2e is suggested to play a role in 
assembly or release of virus particles by interacting with M1.  Although M2e is 
exposed on the virus surface, however, in its native form is poorly immunogenic (Kim 
et al., 2013).  
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To improve immunogenicity, subsequent modifications to the M2-based 
vaccines have included addition of adjuvants and genes that target and improve 
immune function, as well, expression on VLP or liposomal platforms with VLP 
presentation of M2e certainly looking promising (Ebrahimi and Tebianian, 2011).  
Most modifications providing protection against lethal challenge with H1N1, H3N2, 
H5N1 although significant morbidity was still evident.  Although the protective effect 
in mice has been conclusive, extension to other animal models has been 
disappointing (Deng et al., 2015), as well, the observed protective effect has not 
been to the level provided by inactivated vaccines.  Nevertheless, a small phase I 
trial of an M2e flagellin-conjugated vaccine has been conducted in healthy adults, 
with a 4-fold increase in M2e titers observed (Stepanova et al., 2015). 
 
Interestingly, it is proposed that an M2e vaccine, as for other epitope vaccine 
candidates, not to supplant existing vaccination strategies but as an adjuvant to 
mitigate the effects of the disease until a strain specific vaccine is available. 
 
 1.3.4 Nucleoprotein (NP) epitopes 
 
The CTL CD8+ and CD4+ T-cell NP epitopes have been well defined since 
the 1980's, where induced T-cells afford NP specific protection (Ciacci-Zanella et al., 
2010; Gschoesser et al., 2002).  Considering that Influenza nucleoprotein (NP) is 
over 90% conserved between influenza A strains, it has always been the most 
targeted gene for CTL responses where NP or the NP-encoding gene has been 
delivered to numerous animal models using purified NP (Hou et al., 2012; Mbawuike 
et al., 2007), vectored using Adenovirus or Vaccinia virus (Lilie and Berthoud, 2012), 
or as a DNA vaccine (Alexander et al., 2010).  As well, the NP region of live 
attenuated vaccines has also received attention where significant responses were 
found using a 'silent mutation' approach to a highly-conserved region of the 3' end of 
the NP gene (Anhlan et al., 2012).  
 
There are diverging opinions, as always, some studies have shown that 
vaccination with plasmids encoding the NP gene, as in some DNA vaccines, don't 
induce adequate protection against lethal homologous or heterologous influenza 
viruses (Zhong et al., 2010).  Conversely, other studies show heterosubtypic 
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immunity conferring resistance against different influenza virus strains with NP 
epitope peptidesis limited. 
 
Although epitopes of all the major AIV genes have been extensively studied, 
NP epitopes appear the most promising because of their highly-conserved nature, 
found across all the main AIV subtypes (Bastin et al., 1987; Ng et al., 2008).  As well, 
NP epitopes have been widely used in vaccine studies with a proven T-cell response 
(Townsend et al., 1986; Epstein et al., 2005).  Although CTL immunogenicity doesn't 
match humoral antibody response the potential for long lasting immunity combined 
with rapid clearance and reduction in severity and mortality fits well with protecting 
the domesticated bird/poultry industries, the basis of this study.  
 
1.4. Microalgae 
 
Although plants have been the main focus (Kopertekh and Schiemann, 2017), 
over the past 2 decades microalgae have been well studied, both as a natural source 
of bio-compounds and as bioreactors for recombinant protein expression (Bai et al., 
2013; Georgianna et al., 2013; Koo and Park, 2013; Liu et al., 2013; Mouradov and 
Stevenson, 2012; Pelosi et al., 2012; Qin et al, 2003).  In particular, the green 
eukaryotic alga Chlamydomonas reinhardtii has been the subject of considerable 
investigation where recent successes have served to highlight their potential as 
foreign protein expressers (New et al., 2012; Potvin and Zhang, 2010; Twyman et al., 
2012).  
 
C. reinhardtii is a single-celled, motile, green eukaryotic microalgae that 
belongs to the class Chlorophycae within the order Volvocales (Neupert et al., 2012).  
Approximately 500 species of Chlamydomonas have been described, but only a few 
species have been studied, C. reinhardtii being the most studied and manipulated.  
They are an important food source for higher organisms in early stages of the trophic 
chain. Their adaptability to extreme and stressed abiotic conditions such as extreme 
temperatures, high salinity and pH extremes make them of significant environmental 
value. They are very heterogeneous regarding their size and shape and are able to 
live singly, in chains or in groups.  C. reinhardtii has a short generation time, being 
able to double cell population each 5-8 hours and can grow to densities above 107 
cells/ml (Mayfield and Kindle, 1990).  Minimal nutritional requirements and an ease 
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scale-up make its production cost effective (Griesbeck and Kirchmayr, 2012; Noor-
Mohammadi et al., 2012). 
 
C. reinhardtii has an ellipsoid shape and a polar structure with two apical 
flagella.  The cell is surrounded by a wall of hydroxyproline-rich glycoproteins and 
contain several mitochondria and a single cup-shaped chloroplast which occupies 
approximately 40% of the intracellular space surrounding the nucleus and nucleolus 
(Nickelsen and Bohne, 2012; Neupert et al., 2012).  The total size of the cell is about 
10μm in length and 3μm in width.  
 
C. reinhardtii has the most advanced molecular genetic toolkit developed for 
any algae. All three genomes; nuclear, chloroplast and mitochondrial, have been 
sequenced and transformation protocols and vectors are available for each of these 
genomes (Maul et al., 2002; Popescu and Lee, 2007; Merchant et al., 2007; Rasala 
and Mayfield, 2015), and all have been successfully transformed and manipulated 
(Popescu and Lee, 2007; Kindle, 1990; Kindle and Sodeinde, 1994; Neupert et al., 
2012; Mayfield and Kindle, 1990).  As a result of this intensive study, there is a large 
mutant collection available.  
 
The nuclear genome represents the majority of the DNA within the cell, it is 
approximately 121Mb and it is divided into 17 chromosomes (Nickelsen and Kuck, 
2000).  The chloroplast genome contains approximately 99 genes as circular double 
stranded DNA.  The DNA has a length of approximately 196Kb and contains 
approximately 80 copies of the genome, around 20% of the plastid genome is 
repetitive DNA (Maul et al., 2002).  The mitochondrial genome of C. reinhardtii is a 
15.8Kb linear molecule and encodes eight proteins (Popescu and Lee, 2007). 
 
C. reinhardtii is a model system for studying foreign protein expression for 
several reasons;  
 
• C. reinhardtii grows well under controlled artificial conditions and an be grown 
in full containment, so the risk of environmental contamination by a transgenic 
strain is low. 
• Photosynthesis in C. reinhardtii is dispensable if a carbon source such as 
acetic acid is provided in the growth medium, and the organism can then grow 
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Figure 1.6. Schematic representation of the cell architecture  
of C. reinhardtii. Source, www.metamicrobe.com image. 
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photoautotrophically, mixotrophically, or heterotrophically (Neupert et al., 
2012). 
• C. reinhardtii nuclear, chloroplast and mitochondrial DNA is easily 
transformed, and there is a relatively short period of time between the 
generation of initial transformants and scale up to production volumes. 
• A wide variety of promoters that are regulated by factors such as light or 
specific nutrient levels in the medium are available.  
• C. reinhardtii can produce secreted, glycosylated proteins since the strain 
contains eukaryotic protein folding machinery and can produce complex 
proteins on a larger scale without the need for denaturation and refolding 
steps (Specht et al., 2010). 
• C. reinhardtii can be grown in cultures on scales ranging from a few milliliters 
to 500 000 liters in a contained and cost-effective manner.  The low cost 
compared to the conventional mammalian/microbial/yeast fermentation 
systems is a significant research incentive.  
• C. reinhardtii serves as a safe oral delivery vector(GRAS) with the protein 
produced posing little risk of viral, prion or bacterial endotoxin contamination.  
The efficacious oral delivery of gut-active biologics, including a prophylaxis for 
enteric infections, oral vaccines against viral and bacterial pathogens, growth 
hormones for aquaculture, and enzyme supplements for enhance animal 
feeds, without the need of protein purification, represents a significant 
advantage. 
 
 1.4.1. Nuclear transformation 
 
Nuclear genome transformation generally occurs by random insertion through 
non-homologous end-joining (Kindle, 1990; Mayfield and Kindle, 1990).  Nuclear 
genome engineering affords all the advantages associated with eukaryotic 
expression systems, enabling regulated (inducible) transgene expression, efficient 
folding of complex proteins, recombinant protein secretion, protein secretion, and 
post-translational modifications such as disulfide bond formation and glycosylation 
(Michelet et al., 2011). 
 
Limitations of nuclear genome engineering include: 
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▪ Low recombinant protein accumulation due to transgene silencing and 
positional effects, that are not well understood (Cerutti et al., 1997; Wu-
Scharf et al., 2000).  
▪ Targeted genome engineering via traditional homologous recombination is 
very inefficient (Zorin et al., 2005) and has hindered platform optimization. 
▪ The inability of heterologous transgenes to express well in the C. reinhardtii 
genome is due to the presence of a strong codon bias in the nucleus, which 
favors G or C (88%) in the third position (Mayfield, Manuell, 2007). 
 
 1.4.2. Chloroplast transformation 
  
During evolution, plastids are considered to have derived from 
anendosymbiotic cyanobacterium (Gould et al., 2008).  From this ancestor, plastids 
have retained a small autonomous genome that contains approximately a hundred 
genes in Chlamydomonas. From the gram-negative Cyanobacteria, the plastids also 
inherited the two membranes that constitute the envelope, which in secondary or 
tertiary endosymbiotes is surrounded by one or two additional membranes derived 
from the host (Gould et al., 2008).  Accordingly, chloroplasts of green algae contain 
gene expression machinery that is prokaryotic in nature, including the ribosomes and 
translation factors (Manuell et al., 2007).  However, unlike bacteria, the chloroplast 
contains a wide range of chaperones, protein disulfide isomerases and peptidylprolyl 
isomerases (PPIases; Schroda, 2004).  Many studies have demonstrated that the 
chloroplast supports the accumulation of complex, correctly folded and properly 
disulfide bonded soluble recombinant proteins that are biologically active.  Stable 
transformation of the chloroplast requires that all 80 plastid copies convert to the 
recombinant form (homoplasmy; Almaraz-Delgardo et al., 2014; Daniell and 
Edwards, 2011; Day and Goldschmidt-Clermont, 2011; Goldschmidt-Clermont, 1991; 
Gimpel et al., 2015).  The homoplastic state occurs after several plastid and cell 
divisions in the presence of the chosen selective agent.  Unlike nuclear 
transformation, plastid transformation occurs via homologous recombination, hence, 
integration events can be precisely targeted to any region in the chloroplast genome 
that contains a so-called “silent site” for transgene integration and is characterized by 
stable expression and high levels of protein accumulation, typically 1–10 % of total 
protein, but levels as high as 21 % have been reported (Blowers et al., 1989; 
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Eberhard et al., 2002; Specht et al., 2010; Gong et al.,  2011).  Chloroplast 
transformation also permits the development of stable clones due to the maternal 
inheritance of the integrated gene, allows the expression of multiple genes from 
polycistrons, and does not present gene silencing (Leon-Banares et al., 2004).   
 
The most efficient promoters used in chloroplast transformation are; the rbcL 
promoter which corresponds to the ribulose biphosphate carboxylase large subunit, 
the atpA promoter of the ATPase alpha subunit, and the psbA promoter from the 
photosystem II protein D1 (Kindle et al., 1991; Klein et al., 1994, Griesbeck et 
al.,2006).  Of them all, psbA has been found to be the most successful and 
associated with the greater expression.  It is important to consider that the 
chloroplast of C. reinhardtii contains a codon bias which favours at an 80% rate 
adenine (A) and thymine (T) in the third position over guanine (G) and cytosine (C). 
To achieve protein expression, the foreign gene of interest has to first be converted 
to match the codon usage of C. reinhardtii chloroplast, referred to as codon 
optimization (Mayfield et al., 2007; Franklin and Mayfield, 2005; Purton et al., 2013; 
Rasala et al., 2011; Salvador et al.,1993).  
 
C. reinhardtii has been an original model for chloroplast genetics and 
molecular biology that helped pave the way for the development of stable chloroplast 
(plastid) transformation; the aadA marker has long been the established marker 
(Goldschmidt-Clermont, 1991) and methods for marker removal were first 
demonstrated (Cerutti et al., 1997).  The first stable chloroplast transformation was 
achieved in 1988 by microprojectile bombardment of DNA (biolistics) using the model 
organism C. reinhardtii (Boynton et al., 1988).  Since then the transformation 
technique of choice for studies of chloroplast transformation in microalgae has been 
with the use of biolistics.  The gene gun is used to bombard plant cells and organs, or 
a lawn of algal cells on the surface of an agar plate, with micron-sized metal particles 
carrying the DNA of interest.  This technique allows the delivery of transforming DNA 
directly within the chloroplast through the cell wall and at least three membranes, 
including the plasma membrane and envelope, and integrates by homologous 
recombination in the plastid genome of the host.  The whole process however is not 
very efficient, for example in Chlamydomonas, transformed cells appear with a 
frequency of approximately 105. At this frequency, using efficient markers and having 
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low rates of false positives are an important requirement for the recovery of 
successfully transformed cells. 
 
However, chloroplast transformation presents some disadvantages when 
compared with nuclear transformation; 
 
• The chloroplast has no mechanisms for post-translational modifications, 
secretion, or formation of disulphide bonds (Eicher-Staighberg et al., 2009; 
Leon-Banares et al., 2004). 
• While the chloroplast of C. reinhardtii has been shown to support 
expression of a variety of recombinant proteins, the number of successful 
reports remains low, especially in comparison to other expression systems 
such as Escherichia coli, S. cerevisiae and CHO cells. 
• Early attempts to express recombinant proteins in the C. reinhardtii 
chloroplast primarily involved proteins that confer resistance to antibiotics 
(Goldschmidt-Clermont, 1991).  These markers proved useful for selective 
purposes and for gene-disruption experiments, but the levels of 
recombinant protein expressed are quite low and therefore difficult to 
quantify.  
• The inability of heterologous transgenes to express well in the C. 
reinhardtii genome is due to the presence of a strong codon bias in the 
chloroplast, which favors A or T (80%) in the third position (Coragliotti et 
al., 2011). 
 
1.4.3. Chlamydomonas vaccines and therapeutics  
 
Conventional vaccines are injectable, expensive and require skilled medical 
personnel for its administration, and in less well-developed societies can cause 
accidental transmission of other infections.  There is significant interest in producing 
an alternative approach by using recombinant edible vaccines, utilising microalgae 
for example.  Edible vaccines are cost-effective and reduce the need for skilled 
medical personnel and sterile injection conditions (Rosales-Mendoza et al.,2012; 
Specht et al., 2010).  Edible vaccines are easy to store without the need of 
refrigeration, making it possible to store them near where they will be used, and 
being affordable for developing countries (Nochi et al., 2007; Specht and Mayfield, 
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2014; Jones et al., 2013; Gregory and Mayfield, 2014).  Additionally, injection 
administered vaccines only induces a systemic response, unlike edible vaccines 
which elicits both mucosal and systemic immune response.  Mucosal immunization is 
important since it represents the first defence barrier against infectious agents (van 
Riet et al., 2012).  Furthermore, the Chlamydomonas rigid cell wall protects the 
included antigen from rapid degradation in the acidic environment of the stomach.  
 
To date several Chlamydomonas-based vaccine candidates have proved to be 
functional in test animals and functional antibodies have also been produced in this 
host (Lossi and Wayheed, 2011; Rosales Mendoza, 2013; Wang et al., 2012).   Thus 
far, several vaccination models have been reported using Chlamydomonas as a 
source of recombinant vaccines (Rosales-Mendoza et al., 2012; Gregory et al., 2012; 
Gregory et al., 2013).  These include reporter proteins (Franklin and Mayfield, 2004; 
Mayfield and Franklin, 2005; Muto et al., 2009),  a large complex mammalian single-
chain antibody, HBc Ag-based antigen (Soria-Guerra et al., 2013), HSV8-Is 
containing the entire IgA heavy chain protein fused to the variable light chain, more 
traditional single-chain antibodies (Franklin and Mayfield, 2005), a full-length 
monoclonal antibody (Tran et al., 2009; Tran et al., 2013) and potential vaccine 
antigens (Demurtas et al., 2013; Yoon et al., 2013).  The D2 fibronectin-binding 
domain of Staphylococcus aureus fused with the cholera toxin B subunit (CTB-D2) 
have been expressed in C. reinhardtii and used as an oral vaccine (Dreesen et al., 
2010).  The white spot syndrome virus protein 28 (VP28; Surzycki et al., 2009), 
Swine fever virus E2 viral protein CSFV-E2), a variety of other heterologous proteins 
including antibodies, hormones, pharmaceutical proteins, vaccine antigens and 
reporter proteins (Akbari et al., 2014; Gong et al., 2011; Noor-Mohammadi et al., 
2012; Specht and Mayfield, 2014; Sun et al., 2003), all have been expressed in this 
system. 
 
Examples of therapeutic proteins synthesized in microalgae include: the blood 
sugar level-regulating hormone type I (Proinsulin; Rasala et al., 2010), the human 
vascular endothelial growth factor isoform 121 (VEGF; Rasala et al., 2015), E. coli 
phytase (Yoon et al., 2011), the bovine mammary-associated serum amyloid (M-
SAA; Manuell et al., 2007), and the human erythropoietin fused to ARS2 export 
sequence w/6x his tag (ARS2-crEpo-his6; Eichler-Stahlberg et al., 2009).  
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The use of microalgae, viz, C. reinhardtii, in this study was seen to be a 
means to achieve 2 of the stated goals of this project, being cheap to develop as a 
vaccine and fulfilling the edible route as a means to administer the vaccine. The 
chloroplast of C. reinhardtii was chosen as the expression vehicle for NP 
presentation, for it's simple prokaryotic nature and availability of tools already for it's 
transformation; the antibiotic marker aadA and rbcl based vectors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Influenza nucleoprotein expression in microalgae, B. Cooke 
30 
Chapter 2 
Materials and Methods 
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The Materials and Methods chapter is organized to include those procedures 
used throughout this project, being;  
 
2.1. Construction flowcharts 
 Summarizing the methods used for each construct;  
  Table 2.1. pBC1 
  Table 2.2. pBC1+  
  Table 2.3. C. reinhardtii.  
 
2.2. pBC1 and pBC1+ vector construction 
 Chapter 3; pBC1 construction   
  To construct pBC1vector.  Describing the design of the influenza  
 nucleoprotein fragment, including integration of the NP fragment  
 with the PrbcL and TrbcL chloroplast promotor and terminator. 
 
 Chapter 4, pBC1+ construction 
To construct pBC1+ vector. Describing addition of the enzyme sites 
NotI and SacI and the antibiotic resistance marker, aadA (resistance to 
streptomycin and spectinomycin) to pBC1 (constructed in Chapter 3). 
 
2.3. Chlamydomonas reinhardtii transformation.  
 Chapter 5.  C. reinhardtii, transformation 
Describing transformation of C. reinhardtii with the pBC1+ vector 
(pBC1+ vector ex. Chapter 4.) thereby integrating the Influenza NP fragment 
and antibiotic resistance marker, aadA, into the C. reinhardtii chloroplast 
genome.  
 
Confirmation procedures of NP DNA integration in the C. reinhardtii 
chloroplast and NP protein expression are included. 
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Table 2.1.  pBC1 construction flowchart.  
pBC1, a vector constructed from the transformation of a p463 construction vector to 
include the Influenza NP fragment. 
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- 
 
 
 
Table 2.2.  pBC1+ construction flowchart. 
pBC1+, a vector constructed from the transformation of a p463+5a construction 
vector with pBC1. 
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Table 2.3. C. reinhardtii transformation flowchart. 
Transformation of vector, pBC1+ into a C. reinhardtii strain. 
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2.2. pBC1 and pBC1+ vector construction 
 
  2.2.1. NP sequence design 
 4 Bioinformatic tools; Syfpeithi, BIMAS, IEDB and RankPep were 
used to provide the following; 
- The NP epitope that best represented the most immunogenic 
regions of the Influenza nucleoprotein gene. 
- Due to the high polymorphism within the MHC cluster it is not 
only necessary to identify the MHC genotype but also to tailor 
the epitope selection to match the MHC allele restrictions for 
vaccine efficacy testing. 
  - Inclusion of the NcoI and PstI enzyme sites with the   
   NP sequence.  
   
Refer Chapter 3 for bioinformatic results of the sequence design. 
 
A manufacturer was selected to synthesize the NP sequence 
and instructions were followed upon receipt to re-suspend the 
sequence, aliquot and store at -20C.  Prior to use, aliquots were diluted 
to obtain 1-2ng needed for transformation. 
 
  2.2.2. E. coli DH5α competent cell preparation 
10ml LB broth was inoculated from frozen E. coli DH5α frozen 
stock and incubated o/n at 37C on an orbital shaker at 120-140rpm.  
From the incubated 10ml broth, 2ml was removed and inoculated into 
200ml LB broth in either a 1L or 2L flask and incubated at 37C, 
agitating vigorously at approx. 160rpm on an orbital shaker.  The OD 
checked every 30min, the OD reached 0.5 to 0.6 mid log phase, in 
about 2.5hrs, the LB containing flask then cooled immediately on ice for 
20-30min and dispensed into 4 x 50ml falcon tubes, kept cool at all 
times and centrifuged at 4500xg for 15minutes at 4C. The centrifuge 
was cooled to 4C beforehand.  After centrifugation the supernatant was 
decanted from all 4 tubes to waste, tubes with cell pellet stored on ice.  
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10ml of cold sterile ddH2O was added to each cell pellet 
containing tube and left on ice for 60 minutes to re-suspend cell pellet 
then a further 40ml ddH2O was added carefully.  The ddH2O was 
cooled at -20C just prior to use.  The 4x tubes were centrifuged at 
4500xg for 10 minutes at 4C and the supernatant decanted to waste.   
 
After washing, 10ml cold sterile 10% glycerol was added to each 
cell pellet containing tube and left on ice for 60 minutes to re-suspend 
the cell pellet then a further 40ml of the 10% glycerol was added 
carefully.  The 10% glycerol was cooled at -20C just prior to use. The 4 
x tubes were centrifuged at 4500xg for 10 minutes at 4C and the 
supernatant decanted to waste. 
 
Approx. 12.5ml cold sterile 10% glycerol was added to each 
pellet containing tube and left on ice for 60 minutes to re-suspend 
pellet.  The 4 x tubes were combined to 1 tube, centrifuged at 4500xg 
for 10 minutes at 4C and the supernatant decanted to waste. 
 
600μl of 10% glycerol was added to the cell pellet containing 
tube and left for 60 minutes to re-suspend pellet.  The re-suspended 
pellet dispensed in 50μl volumes, into sterile microtubes, the tubes 
frozen in dry ice and stored at -80C. 
 
  Solutions: 
  10% glycerol 
   10g 100% glycerol to 90mls dd H2O 
   
  LB broth (Luria- Bertani), volume, 1Litre. 
 
   Ingredient   weight 
   Tryptone   10g 
   Yeast extract   5g 
   Sodium chloride  10g 
    Adjust pH to 7.0.   
   
Alternative competent cell preparation: 
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Bioline Ltd, manufactured chemical competent E. coli DH5α 
were also utilized.  Method of use was as described in Bioline's 
protocol. 
 
  2.2.3. Transformation, electroporation 
  Biorad Gene pulser and controller electroporator. 
   
A microtube of E. coli DH5α competent cells (Method 2.2.2) from 
-80C was thawed at room temperature then transferred to ice.  To the 
50µl of competent cells/ tube, 1-2 µl (2-4ng) of NP DNA (Method 2.2.1) 
was added, a total volume of approx. 52µl. 
 
The DNA/cell mix was transferred to an electrocuvette, 
previously cooled on ice.  The electrocuvette has either a blue cap 
(1mm) or pink cap (2mm).  The electroporator settings are determined 
by the electrocurvette used.  For the 2mm curvette the electroporator 
was set to the following: 2.3KV to 2.5KV, 35mF, 200Ω.  For the 1mm 
cuvette, the settings were 1.8KV to 2.0KV, 35mF, 200Ω.  If a DNA 
solution is suspected to have a high salt loading e.g. a ligation mix, 
then the voltage can be reduced slightly. 
 
The DNA/cell containing cuvette placed into the BioRad cuvette 
holder, the cuvette holder stored previously in the -20C fridge, and 
inserted into the electroporator.  The 2 buttons on the electroporator 
were pressed simultaneously until a ‘beep’ was heard then immediately 
released.   
 
The DNA/cell containing cuvette removed from the cuvette 
holder and 1ml immediately added of prewarmed LB broth, no 
ampicillin, the LB broth was prewarmed to 37C.  The LB broth/DNA 
then removed from the cuvette and pipetted into a sterile microtube and 
incubated for 1 hour at 37C.  
  
Aliquots (different volumes) of the LB broth/DNA are removed 
from the microtube were plated onto the surface of pre-dried LB agar + 
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100µg/ml ampicillin.  All plates incubated at 37C for 16hrs.  NP 
containing transformants are normal colony size, nm cream in colour.  
Non-transformed E. coli DH5α don't grow. If LB agar is incubated longer 
than 16hrs, satellite colonies can appear that do not contain the NP 
plasmid.   
  
Note:  
1.  If a 'pop' is heard when pushing on the electroporator buttons 
during transformation, the 'pop' indicates the DNA/cell mix has 
contamination present, possibly a high salt concentration in the 
DNA preparation, the DNA needs to be further cleaned up to 
remove the contaminants.  More commonly, the competent cells 
have failed and need to be prepared again.  
2. Normally DNA quantification is undertaken prior to 
electroporation, by spectrophotometry.  From this value the DNA 
of the sample is adjusted, usually by dilution, to ensure 2-4ng 
DNA is available for electroporation.   
 
2.2.4.  Transformation, TA cloning kit 
  Invitrogen TA cloning kit, 2.1. 
 
 The cloning kit relies on the ability of adenine and thymine on 
different DNA fragments used in the mix to hybridize and, in the 
presence ligase, ligate together. The PCR Taq preferentially adds an 
adenine to the 3' end of the DNA and is cloned into linearized vectors 
that have complementary 3' thymine overhangs. 
   
 Instructions were followed as described in the Invitrogen 
protocol.  The transformed colonies are identified by colour; the non- 
transformed colonies are colored blue and transformed colonies are 
colored white. 
 
2.2.5. DNA recovery 
Bioline, Isolate Plasmid DNA Mini Kit 
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DNA is recovered from representative transformed colonies after 
transformation.  Usually between 4-6 transformants are selected to 
have their DNA recovered. 
 
A single transformed colony is inoculated from LB agar into 5ml 
LB broth + ampicillin (100μg/μl) and incubated for 16hr at 37C with 
vigorous agitation. 
  
The incubated LB broth is centrifuged after incubation at 4000g 
for 5minutes and the supernatant discarded.  The cell pellet is re-
suspended in Bioline resuspension buffer, 250μl as for high copy 
plasmid, and vortexed to breakup the cell pellet then the volume/cells 
transferred to a 1.5ml sterile microtube.  The procedure then followed 
as described in the Bioline protocol.  The final Elution volume of 30μl, 
not 50μl, was used to ensure adequate DNA concentration. 
 
The quantity and quality of recovered DNA was then checked by 
spectrophotometry.  The spectrophotometer 260/280 ratio should be 
close to '1.8' for the DNA quality check.  Although a quantity indication 
can be made by spectrophotometry, DNA quantification was always 
confirmed by agarose electrophoresis (Method 2.2.6). 
 
   2.2.6.  DNA agarose electrophoresis 
  Biorad gel doc UV/VIS illuminator protocol 
  Biorad powerpac basic, instructions 
  
1.0-1.5% agarose, dependent on preference, was weighed into a 
clean 250ml Erlenmeyer flask and TAE buffer added to makeup the 
required volume.  50ml of the agarose solution was used for a mini-
plate for up to 7 samples.  100ml of agarose solution was used for a 
midi-plate for up to 15 samples.  The agarose solution then microwaved  
slightly then poured into a mini or midi-plate mould appropriate for 
agaose volume being used and the well forming comb fitted.  The 
agarose solution is allowed to set into a gel.  Upon setting the plate and 
gel are placed into the electrophoresis bath.  Using 1x TAE buffer 
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solution, the buffer solution level is adjusted in the bath so to just cover 
the gel and plate then the well forming comb can be removed from the 
gel. 
 
The DNA samples were prepared, where; the DNA sample 
volume is first mixed with 2µl of 5x loading gel and dd H2O added, to a 
final volume of 20µl. 
 
The DNA sample volumes were added to the gel wells, one 
sample/well.  The DNA λ marker added to the first well on the plate, 
normally 10µl was added to reflect the correct weight of the λ marker. 
 
After all samples were added, the Biorad powerpac was turned 
on and settings adjusted.  The voltage set to 120mV, the mA set to 
400, usually always the default, and the timer set for 50-60min.  The 
voltage is dependent on gel strength used and size of DNA of 
interest,120mV was suitable for this study. 
 
After the timed run was completed the gel/plate was lifted out of 
the electrophoresis bath, the gel carefully slid off the plate into the 
ethidium bromide solution.  The gel left in the ethidium solution for 5-
10min.  After this time the gel was removed from the ethidium solution 
and placed into a water rinse bath and left in the rinsing bath for 30min.  
The water input into the rinse bath adjusted to provide a steady flow of 
fresh water.    
 
The gel removed from the rinsing bath and placed into the 
BioradUV/VIS gel illuminator for viewing and quantifying. 
 
  Solutions: 
  1.0 -1.5% Agarose   
  TAE buffer s/s, to either 50 or 100ml 
   50x TAE buffer stock 
   Ingredient  Quantity 
   Tris, 2M  242.2g 
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   Acetic acid, 1M 60ml 
   EDTA, 0.1M  37.2g 
   dd H2O  to 1L (final) 
  
   Sufficient volume of 50x TAE used to prepare a 1x   
   TAE working solution. 
 
  Ethidium bromide solution 
   Ethidium bromide stock solution, 10mg/ml 
 
   600μl of stock solution was transferred to an    
   ethidium bromide staining tray. 
      
   Water, double distilled (milliQ), 1litre, was added to   
   the staining tray and swirled gently to mix with    
   ethidium stock added. 
 
  DNA ladder 
A PstI digestion of Lambda phage DNA was used to provide a 
DNA ladder for identifying and quantifying DNA samples, from 
247bp to 11500bp. 
    
BioLine 1kb hyperladder, was also used in some instances to 
provide a DNA identification and quantification, range from 
200bp to 10037bp. 
 
   Refer Figure 2.2. 
 
  2.2.7. Digestion 
  DNA recovered, Method 2.2.5.  
   NEB enzyme digestion protocol; NcoI, PstI, NotI, SacI  
   enzymes were used in this project. 
   
The DNA added to be digested is depended on stated enzyme 
digestion activity, normally 1μg of DNA digested is aimed for. 
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For all enzymes, 1 unit of enzyme digests 1μg DNA at selected 
temperature.  The volume of enzyme needed to digest DNA quantity 
was added.  Normally, 1μl of enzyme is sufficient and will contain more 
enzyme than needed.  Single enzyme and double enzyme digestion 
was conducted.  Double digestion occurred mainly with PstI and NcoI 
enzymes, both were added at the same time utilizing an appropriate 
buffer compatible for both enzymes. Single digestion occurred for 
SacI/NotI enzymes. 
 
For double-digestion the following was added to a microtube: 
 
   DNA    volume dependent on DNA conc. 
   Digestion buffer, x10  5μl 
   Enzymes, 1μl each  2 μl  
   BSA, 10mg/ml  0.5μl 
   ddH2O   volume dependent on DNA  
   Total volume   50μl   
   Incubate at 37C for 1-2 hrs. 
   
After digestion a DNA agarose electrophoresis was undertaken, 
Method 2.2.6, 2-3 μl of digested product was used.  Two bands are 
evident; the required band at the anticipated size and a bigger band at 
reduced size to the original DNA.  If a band comparable to the original 
DNA size only was found with no secondary DNA band, digestion was 
repeated and digestion time extended.  
 
  2.2.8. DNA gel extraction 
  QIAGEN QIA quick gel extraction kit protocol 
 
A DNA electrophoresis gel was conducted, Method 2.2.7, the 
'midi' plate only was used requiring 100ml 1.5% agarose, and all of the 
digestion product was loaded (50μl) and spread over 2 wells of the gel.  
Upon completion of electrophoresis, a visual of the gel was made and 
image recorded in the Biorad UV illuminator to ensure digested DNA 
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bands are where they should be.  Care was exercised not to expose 
the DNA any longer than necessary to the short length UV light since 
changes can occur to the DNA. 
 
The microtubes to be used during extraction were weighed, to 
obtain their initial weight, and all needed supplies were taken to the 
'Dark Room' that contained the bench DNA illuminator.  This illuminator 
has a longer length UV light that doesn't affect the DNA over the time 
taken to excise the DNA from the gel. 
   
Using a clean scalpel blade for each sample, incisions were 
made in the gel around each illuminated DNA band of the size to be 
extracted, and using the same blade the DNA containing gel piece was 
removed from the gel and put into the pre-weighed microtube. The 
remaining gel was discarded.  The remaining gel after extraction can 
be re-imaged in the Biorad illuminator and the image saved to verify the 
correct bands were excised, for a later time.  
 
The microtube, now containing the DNA gel piece, was 
reweighed to determine volume of buffer to be added to solubilize the 
gel to enable DNA removal.  The DNA was removed from the gel 
containing DNA using the QIAGEN gel kit.   
 
The DNA is eluted from the QIAGEN kit column with 30μl, using 
either ddH2O or Elution buffer, to maximize DNA conc. since 20% of 
DNA can be lost during DNA removal. 
 
DNA purity can be checked by spectrophotometry using the 
'Nanodrop' and by undertaking an agarose electrophoresis (Method 
2.2.6) to quantify the extracted DNA. 
 
2.2.9. DNA concentration 
The procedure was used sometimes following either DNA 
digestion or DNA gel extraction if the DNA recovery was low.  This  
 
 
Influenza nucleoprotein expression in microalgae, B. Cooke 
44 
 
 
 
 
 
           λ-PstI DNA ladder      BioLine 1Kbp hyperladder 
   
 Figure 2.1.  DNA ladders used in Agarose electrophoresis.   
 λ-PstI ladder and Bioline 1Kbp hyperladder. 
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procedure can also incur a loss of between 10-20% DNA. The DNA so 
concentrated was normally used for ligation. 
 
  To a clean/sterile microtube the following was added; 
 
Total DNA volume from either DNA digestion or DNA gel 
 extraction;   20-25μl 
   96% ethanol;  50μl 
    sodium acetate;  2μl 
 
The microtube vortexed to mix and left at RT for 10 minutes.  
Then centrifuged at 'max' in a bench centrifuge for 15 minutes and the 
supernatant discarded. 200μl 70% ethanol was added to the pellet and 
vortexed briefly then centrifuged at 'max' in bench centrifuge for 2 
minutes, the supernatant discarded.  The DNA remains in the pellet.  
The DNA is air-dried either by a bunsen flame or in a laminar flow 
cabinet for 5-15 minutes. The DNA is re-suspended with 10μl elution 
buffer or ddH20. 
   
  Solutions: 
   Sodium acetate 
   Weigh 24.61g sodium acetate to 100mls ddH2O. 
  Elution buffer  
   Ex. Bioline DNA mini kit can be used. 
  
  2.2.10. Ligation   
 The DNA used is that DNA recovered from the 2 DNA sources, 
Vector and Insert, ex. agarose electrophoresis (Method 2.2.6),  
 
 DNA quantification was first determined from the gel to estimate 
the DNA concentration for both.  
 
 The Vector:Insert molar DNA ratio was then calculated using the 
following formulae: 
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  ng of vector x Kb size of Insert   x (Molar)  Insert   =   ng of Insert 
   Kb size of vector   (Ratio)Vector 
 
   Example 1: 
    ‘ng size of vector DNA’         100ng 
    ‘Kb size of vector DNA’  p463, 4.8kb 
   ‘Size of Insert'   NP_NocI_PstI, 332bp 
   ‘Molar Ratio’,    Insert:Vector  3:1 
   Then: 
   100 x  0.332  x  3 = 20.75ng Insert is required 
    4.8  1 
 
   That is; 100ng Vector to 20.75ng Insert. 
  
 The 3:1 molar ratio was used for ligation together with another 
ratio, 1:1 and/or 1:2.   
  
 The Vector DNA content ex. DNA extraction from an agarose gel 
can sometimes be low, where DNA may need to be concentrated to a 
level that can be used for ligation.  A typical ligation reaction requires 
100-200ng of vector DNA. The DNA concentration is undertaken by 
using the ‘DNA concentration’, Method, 2.1.9.  
   
   Example 2: 
   Vector DNA content ex. gel  8.84ng/µl 
   Total extracted DNA volume  30µl 
   Total Vector DNA recovered   265ng   
   
   Since vector DNA will need to be conc. for ligation, as  
   mentioned a 10-20% loss incurs, so final vector DNA estimate is 
   approx. 212ng or 21.2ng/ul in the 10µl DNA concentration  
   volume.  This can be checked by analysing DNA content by  
   spectrophotometry, using the Nanodrop. 
 
  The ligation reaction volume added to a microtube would be: 
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   Vector  5.1ul (using above example, to achieve   
     approx. 100ng) 
   Insert  1ul (approx. 20.75ng) 
   T4 Buffer 1ul (Promega) 
   T4 ligase 1ul (Promega) 
   ddH2O 1.9ul 
   Total volume 10ul 
  
   The T4 ligase was added last and the microtube cooled  
   on ice immediately.  Since ‘sticky ends’ are required the  
   microtube with mix is incubated at 16C overnight in a PCR  
   heating block or at 4C overnight.   
   
  Solutions: 
  T4 Ligase enzyme and buffer (Promega). 
 
  Ligation controls included: 
1. Uncut vector and ligase. Expected, 'Good vector growth'. 
2. Uncut vector, no ligase. Expected, 'Good vector growth'. 
3. Cut vector (single cut) + ligase. Expected, 'Good vector 
growth'. 
4. Cut vector (single cut), no ligase. Expected, 'Some 
growth'. 
   5. Insert + ligase. Expected, 'No growth'. 
 
  2.2.11. PCR 
  AB Allied Biosystems, Veriti 96 well thermal cycler 
  NEB Taq PCR mastermix, M0270. 
   
  2 sets of primers were used: 
 
Primer1. The nucleoprotein primer was designed using Clone 
Manager software and forwarded to Geneworks for 
synthesizing; 
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    FWD 5’… GGT TTA TAT TCA ATG TGT ACA G, 22bp. 
    REV 5’… CGA AAT GGA TCA ATA CCA AC, 20bp. 
     
Primer2. The C. reinhardtii 'rbcl' primers inclusive NotI/SacI 
enzyme sites were provided by RMIT Plant Biotechnology 
laboratory (Dressen et al., 2010). 
   fwd, 5′ -gtgatccgcggccgcatgggtttataggtattttgagacc-3′  
    rev, 5′ -gtgatccgagctcgtatgttactatttcttttattacttataaaatataatac- 3′ 
 
The NP primers were re-suspended according to Geneworks 
instructions, alquoted and stored at -20C.  Prior to use 1μl of stock was 
diluted such that 1μl contained 10pM primer and used at that strength 
for PCR. 
 
Transformant DNA recovered and ingredients were added as 
described in the PCR mix with PCR settings as described. 
 
Upon completion of PCR, volumes were checked by DNA 
agarose electrophoresis, Method 2.2.7, for the correct band size.  
The PCR was used a confirmatory step, that the transformed colony 
contained the targeted sequence.  As well, another PCR variation was 
used in this study where PCR was undertaken using the C. reinhardtii 
primers to add enzyme sites, NotI and SacI, into a DNA fragment. 
 
  Solutions and settings: 
   PCR mix 
   Ingredient    Volume 
   DNA     varied 
   Taq Mastermix,x2   12.5μl 
   Primer, fwd    2μl 
   Primer, rev    2μl 
   dd H2O    varied 
        25 μl 
   Water added was dependent on DNA volume.   
   DNA conc. added to PCR should lie between 1 ng–1 μg. 
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  PCR program 
   Cycles:    30 or 35 
   Hot start setting:   95C/1min 
   Denature setting:   95C/15s 
   Anneal setting:   56C/30s 
   Elongation setting:   68C/60s 
   Final elongation setting:  68C/5min 
   Completion:    4C 
   
  Primers 
   1μl of each primer contains 10pmol primer. 
 
  Colony PCR 
Colony PCR was sometimes performed; where part of a 
'transformed' colony was picked off with a wire loop/sterile toothpick 
and inoculated both into the PCR mix, and 'dragged/patched' over a 
small area of a LB agar + ampicillin (100μg/ml) plate.  The LB+amp 
plate incubated at 37C for 16-24hr. 
 
  2.2.12. Sequencing  
  AGRF protocol for Sanger sequencing. 
   
The appropriate aliquot of PCR product, Method 2.2.11, combined with 
the appropriate forward primer and sent to AGRF for analysis. 
 
2.3. C. reinhardtii  TRANSFORMATION 
 
  2.3.1. C. reinhardtii cultivation  
  Invitogen, Countess automated cell counter. 
   
Chlamydomonas reinhardtii, wild type strain, CC124, was used 
throughout this study. 
 
   http://www.chlamycollection.org/product/cc-124-wild-type-mt- 137c/ 
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Chlamydomonas was grown in 100ml TAP medium for 3 days at 
25C in 24hr light (light intensity 3 klux) on a rotary orbital shaker to late 
log phase.  The growth at this time was associated with a dark green 
colouration (106/ml).  The count was checked by the cell counter.  
 
Sufficient cells were transferred to fresh 400ml TAP medium in a 
2L flask to obtain a final cell conc. of approx. 105/ml, the amount 
transferred required usually 10ml of the 3 day100ml culture.  The 
400ml TAP medium was incubated for 2-3 days under the same 
conditions as the original 100ml medium, and a cell conc. of approx. 
107/ml was realized. 
 
After incubation the 400ml culture was centrifuged at 2000g for 5 
min and supernatant discarded.  The cell pellet was re-suspended in 
40ml TAP medium (107/ml) and 0.5ml inoculated onto the center, 3-
5cm, of a dried TAP agar plate (no antibiotic).  This plate was used for 
transformation, where for each transformation 10 such plates were 
prepared. 
   
The inoculated culture on the TAP surface must be absorbed 
before biolistics is commenced. Control plates were also prepared 
where 0.5ml of culture was spread over the surface of a TAP plate (no 
antibiotics) and a TAP + spectinomycin or ampicillin plate.  These 
plates are the +ve and -ve control plates.  
   
  Solutions: 
  TAP medium (Tris-Acetate-Phosphate), as described in the   
  Culture collection of cryophilic algae, CCCryo. 
 
   The stock solutions are prepared as described, and mixed  
  in given order; 
    Tris    2.46g   
    TAP salts    25ml 
    Phosphate solution  1ml  
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    pH is adjusted to pH 7.0 with Acetic acid. 
     
    Hutners trace elements 1ml of stock solution 
    dd H2O   to 1L (final) 
 
   Sterilized at 121C for 20minutes.  
 
Agar can be added to prepare a solid medium (1.0-1.3% 
agar).  The antibiotic, Spectinomycin, can be added to achieve a 
final conc. of 100µg/ml. 
 
  2.3.2. pBC1+ DNA preparation 
    Biolistics mediated by St, Augustine nuclear transformation,  
  Protocol #250. Plant Biotech, RMIT. 
 
  As described in the document with the following modifications: 
  
- pBC1+ vector DNA, shown by PCR and sequencing to contain the 
NP sequence, was used as the DNA source for C. reinhardtii 
transformation. Since the biolistic transformation procedure required 
10 'shots', 10μg pBC1+ DNA was needed, at 1μg/μl DNA per 'shot'. 
 
- 10mg gold particles was weighed into a clean microtube and 
cleaned as described.  Particles resuspended after final wash in 
240μl sterile ddH2O and stored on ice.  
- To 240μl gold particle suspension, vortexed at a slow speed, the 
following components were mixed in given order; 
   10μl DNA 
   250μl 2.5M CaCL2 
   50μl spermidine 
   
The documented procedure was followed, except 600μl 100% 
ethanol not 200μl was used for washing.  Final suspension was in 65μl 
100% ethanol and 6μl/shot was used.  The 6μl was spread onto the 
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center of each of 10 macrocarriers, approx. 1cm in diameter, then let 
dry.   
 
It is crucial that slow vortexing occurs throughout this procedure 
to ensure an even spread of components, and all components are in 
contact with each other. 
 
  2.3.3. Transformation 
  Biolistics mediated by St, Augustine nuclear transformation,   
  Protocol #250. Plant Biotech, RMIT. 
 
   The Biorad biolistic device was setup according to the  
  manufacturers instructions and the requirements of the RMIT  
  Plant Biotechnology department.  There is a need to operate the  
  device safely and to ensure the integrity of each sample. 
 
The C. reinhardtii transformation agar plate was inserted on the 
2nd shelf from the bottom with lid removed.  The helium 'shot' force was 
set to rupture the 1100psi rupture disks where 1 'shot'/rupture 
disc/transformation plate was used.  The device disassembled between 
each 'shot'; replacing both the rupture disc and macrocarrier, and a new 
transformation plate inserted. 
 
  2.3.4. Transformant selection 
   After bombardment, the 10 transformation plates were  
  incubated in darkness at 25C for 24hrs. 
The C. reinhardtii cells from each plate were removed using 
500μl of either sterile water or TAP medium, washed off or very gently 
scraped with a sterile glass spreader.  The resultant C. reinhardtii 
suspension was then spread over the surface of a dried TAP + 
spectinomycin (100μg/ml) antibiotic containing agar plate, 10 plates in 
all.  The agar plates then incubated at 25C in 24hr light for a period of 
up to 10 days for development of possible transgenic colonies 
(putative). This growth is normally evident after 2 -5 days, putative 
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growth was seen as dark green coloured colonies, both large and 
small.   
 
All putative growth was removed upon been viewed with a sterile 
wire /loop and re-inoculated into a 12 or 24 well microtitre plate 
containing TAP + spectinomyin (100μg/ml) broth and onto a fresh TAP 
+ spectinomyin (100μg/ml) agar plate, and incubated in 24hr light at 
25C for visible C. reinhardtii growth.  
 
This latter step is a confirmation step that the transformed 
antibiotic resistance to spectinomycin is stable.  A large number of C. 
reinhardtii cells that appear on the initial plates after bombardment will 
not grow upon re-inoculation. There is a low transformation frequency 
associated with chloroplast transformation.  
 
There is also a need to regrow those transformants that show 
stable growth in TAP containing spectinomycin at least 7 to10 times to 
confirm the transformants are transgenic. 
 
  2.3.5. DNA recovery  
  CTAB/PEG method for Isolation of Genomic DNA from plant   
  tissue, Protocol #220. Plant Biotech, RMIT. 
  
   As described in the protocol for '400mg F/W', with the   
  following modifications; 
 
   The transformed C. reinhardtii culture was grown in 100ml  
  TAP/spectinomycin medium, 72hr(106/ml).  C. reinhardtii cell  
  yields of approx. 700mg wet weight were obtained. 
 
1ml of CTAB was added to 400mg cells and re-suspended, then 
ground in liquid nitrogen.  RNAse A (5mg/ml), 50 μl/ml final, and 0.8vol 
3M KOAC were added. 
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   DNA checked for purity and quantity by spectrophotometry,  
  the 260/280nm ratio check for purity should be approx 1.8.  DNA  
  was then visualized and quantified by DNA agarose    
  electrophoresis (Method 2.2.6). 
 
   The DNA was suspended or diluted to a conc. 1μg/μl before  
  PCR.  
 
  Solutions: 
  CTAB/PEG buffer: 
   Cetyltrimethyl ammonium bromide (CTAB), 10% stock in  
   water (stored at 37C to avoid precipitation, can be stored at  
   this temperature for several years). 
 
   Reagent To add to 10ml final  Final conc. 
   CTAB,10%   3ml  3% 
   NaCL,5M   2.8ml  28% 
   EDTA,0.5M, pH 8  0.4ml  4% 
   Tris-HCL,1M, pH 8  1ml  10% 
   Polyethylene glycol, 
   PEG 6000   0.1g  1% 
   α-mercaptoethanol  0.02ml 0.2% 
   ddH2O   2.68ml 26.8% 
    α-mercaptoethanol added to final mix after grinding,  
   2μl/ml. 
 
  2.3.6. PCR 
  As described in Method 2.2.11. 
  Primers, as used for Influenza nucleoprotein. 
 
  2.3.7. DNA electrophoresis 
  As described in Method 2.2.6. 
  The band of interest will be 332bp in size, the NP epitope   
  sequence. 
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  2.3.8. Sequencing 
  AGRF protocol for Sanger sequencing. 
  As described in Method 2.2.12. 
 
  2.3.9  Protein recovery 
   100ml, 72hr culture of C. reinhardtii was pelleted at 2000g  
  for 5 minutes, the supernatant discarded, where 700mg to   
  900mg of wet cell weight was normally recovered. 
 
The C. reinhardtii pellet was re-suspended in an equal volume of 
double distilled water initially then 2x Tris/SDS buffer added, left 10-15 
minutes and the mix ground in liquid nitrogen to a fine powder then 
stored on ice for 1 hr.  The mix centrifuged at 12,000g for 15 min at 4C.  
The supernatant removed and stored as aliquots at -20C, the pellet 
discarded. 
 
The protein recovered was quantified by the Bradford assay. 
Since SDS was used during extraction the SDS must be less than 0.1% 
in the assay volume.  This is achievable since only a small amount of 
SDS is present in the volume used for the assay. 
   
   The protein level being targeted is 13kDa, the protein equivalent 
  of the nucleoprotein DNA of 332bp. 
 
  Solutions: 
  2x Tris/SDS buffer (modified Laemmli buffer) 
   Reagent   2x(10ml)  Final 
   1.5M Tris-HCL, pH 6.8 800μl   60mM 
   20% SDS   2ml   2% 
   Glycerol,100%  2ml   10% 
   1M EDTA   200μl   10mM 
   α-mercaptoethanol  70μl   50mM 
   dd H2O   5.6mls 
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    α-mercaptoethanol added to final volume after   
   grinding (7μl/ml).  
 
  Note: 
Good protein recovery was also obtained, confirmed by agarose 
electrophoresis, using a 0.2M NaOH/4% SDS lysis of C. reinhardtii.  
This procedure did not require liquid nitrogen with grinding.  However, 
although protein recovery and protein profiles were acceptable and 
detailed, and included the small proteins, the pH of the lysis conditions 
was high at pH 11.  Since some problems were being encountered with 
detecting protein expression this method was discontinued with in 
favour of the Tris/SDS lysis method, described previously. 
   
Other C. reinhardtii lysis protocols were also looked into that 
didn't require grinding with liquid nitrogen, including; sonication and 
combinations of SDS concentrations up to 10% and NaCL.  They were 
disgarded since the chloroplast protein recovery using these protocols 
was found to be low and variable. 
 
  2.3.10. Bradford assay, protein quantification 
  Protein standards were prepared using a BSA stock of 1mg/ml in  
  0.15M NaCL. 
 
  Refer Table 2.4. 
 
The protein samples to be quantified were setup to 100μl total 
volume, being; 10μl sample and 90μl 0.15M NaCL.  Some samples 
were diluted in order to record a Bradford protein level reading within 
the standard range. 
 
From previously prepared Bradford reagent (refer composition 
below) a suitable volume was filtered and 900μl of filtered reagent 
added to each previously prepared standard and sample solution.  The 
mix allowed to sit for approx. 2 minutes. 
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   200μl was transferred from each solution and pipetted in  
  duplicate into a 96 well plastic assay plate.  The absorbance read  
  at 595nm on a Biorad plate reader. 
 
A time lapse between preparing the assay plate and reading on 
the plate reader, upwards of 20-30 minutes is acceptable.  This was 
adhered to. 
 
Note: usually empty wells absorbance are in the range of 0.035-0.045.  
The protein controls used here were in the range of 0.165-0.185. 
 
  Spectrophotometry, Nanodrop 
For a rapid and quick estimation to check if protein recovery has 
occurred, this method can be used.  However, the Protein 
concentration estimate is greater than that obtained by the Bradford 
assay. 
 
  2.3.11. Protein SDS-PAGE  
  SDS-PAGE recipe for small proteins, Thermo Scientific protocol, 2012. 
  Coomassie Blue stain solution, provided by supplier. 
  Biorad, model 3000xi generator, electrophoresis protocol. 
  Biorad Precision protein standards, 'unstained', 10KD to 250KD. 
 
   As described in the described documents with the following  
  additions and modifications; 
   
Two gels were prepared at the same time; 1 gel for total protein 
visualization and counterstained with Coomassie Blue, second gel for 
Western Blot. The gels were constructed according to the BioRad gel 
preparation protocol. 
 
Prior to electrophoresis the previously prepared protein sample 
was thawed on ice and varied volumes of sample added to 5x Laemmli 
buffer, together with ddH2O, to a total volume of 20μl and heated to  
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(μl) Blank S1 S2 S3 S4 S5 S6 S7 S8 
BSA 
stock 
(1mg/ml) 
0 0  3 6 9 12 15 18 21 
0.15M 
NaCL 
100 100 97 94 91 88 85 82 79 
BSA 
conc. 
(ug/ml) 
0 0 30 60 90 120 150 180 210 
 
Table 2.4. Typical Protein standard curve concentration volumes.  From BSA 
stock(1mg/ml) and NaCl diluent to 100μl. 
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95C for 5 minutes to denature the protein.  The samples immediately 
stored on ice after. 
 
   A protein marker ladder was added to one well of each gel, a 
  volume of 10μl/well.  
 
The volume of sample protein loaded depends on protein conc., 
as determined by Bradford assay, usually 2mg/ml/well protein was 
added.  The concentration was varied to determine the optimum 
concentration to produce good band intensities on the gel, particularly 
in the 10-15kDa range.  The targeted range for nuceloprotein 
expression. 
 
The electrophoresis was run at 60v for the first 30 minutes then 
180v for a further 50 minutes, this is the default setting for the 
instrument used. 
 
After electrophoresis the gel(s) were carefully removed from between 
the glass plates in a distilled water containing plastic tub, using a Biorad 
plastic spacer.  The fragile gels gently washed 2x with distilled water 
separately.  The gels remain in their respective tubs on completion of 
washing, the water drained from one.  This gel was then covered with 
approx. 20ml of Coomassie blue solution and placed on a slowly 
rotating orbital shaker table at room temperature and left for 20minutes 
or longer, until the protein bands were clearly discernable.  The 
Coomassie blue solution was removed and the gel washed 2x in 
distilled water to remove excess dye.  The gel then placed between 2 
clear plastic sheets and the image scanned for later study.  
 
   The remaining gel was used for Western Blot, refer 2.3.12. 
   
  Solutions: 
  10x Tricine running buffer prepared as follows; 
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   Reagent   x10/1L 
   Tris base   121.1g (1M)  
   Tricine   179.2g (1M)  
   SDS, 20% stock  50ml (1%) 
  
   pH adjusted to 8.3 
   Total volume 1L.   
   The TRB is used at 1x. 
 
  5x modified Laemmli buffer, total volume 10ml 
   Reagent   x5  Final 
   3M Tris-HCL, pH 6.8 1ml  60mM 
   SDS, 30%   3.33ml 2% 
   Glycerol,100%  5ml  10% 
   EDTA,1M   0.5ml  10mM 
   Bromophenol blue, 1% 0.5ml  0.01% 
   α-mercaptoethanol,14,2M 0.2ml  50mM 
 
   Normally, α-mercaptoethanol is added to LB just   
   before use.  
 
  2.3.12. Western blot 
  Invitrogen iBlot gel transfer 
  Biorad Precision protein standards 'kaleidoscope' ladder, 10kD -250kD. 
  BCIP/NBT substrate, Roche product  
  Primary antibody;  
Influenza, polyclonal, RMIT 'in-house' PR8 extract, rabbit, 
1mg/ml. 
   NP, H1N1, Sino Biological, polyclonal, Rabbit, 100μg. 
Secondary antibody (anti-species conjugate), ABD Serotec:  
   Anti-rabbit antibody conjugated to AP. 
  Positive control, Influenza H1N1 PR8 RMIT laboratory strain   
   virus. 
  Negative control, Protein extract, C. reinhardtii non-transformed  
   WT strain. 
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  Protein SDS page gel prepared as described, Method 2.3.11.  
 
Western stained protein marker at 10μl/well was loaded into 1 
well and sample conc./well added as described in Method 2.3.11.  After 
electrophoresis then rinsing in water, the gel removed from the 
container and transferred onto an iBlot nitrocellulose membrane, as 
described in the iBlot instructions.  The iBlot commenced using the 
default time of 7 minutes. The membrane removed after this time and 
placed into a small plastic tub.   
 
Blocking solution added.  5% skim milk-powder in TBS, 20-30mls was 
used, skim milk-powder tended to minimize non-specific antibody 
binding. The tub placed onto a slow rotating orbital shaker and 'blocked' 
for 2hr at room temperature.  After 'blocking', the blocking solution was 
discarded to waste and the membrane washed in TBS; 2 washes x 5 
minutes, 20-30mls TBS for each wash. 
 
Primary antibody added. The antibody conc. was varied from 1:5000 to 
1:10,000 in 1% skim milk-powder/TBS, 15-20mls was used. Incubation 
was for 2hr at room temperature on a slowly rotating table.  After, the 
primary antibody was removed, the antibody can be stored at 4C for 
future reuse, the membrane was washed in TBS; 2 washes x 5 
minutes, 20-30mls for each wash. 
 
Secondary antibody added. The concentration used was 1:5000 diluted 
in 1% skim milk-powder/TBS, 15-20mls was used.  Incubation was 2hr 
at room temperature.  The antibody removed and discarded, the 
membrane was then washed 2 x 5minutes in TBS, 20-30mls for each 
wash.  A third wash was introduced using TBS + 0.05% Tween 20; 1 x 
5minutes. 
   
The membrane was placed into detection buffer (DB) for 5 minutes. the 
DB removed and 5ml of AP substrate (APS) added for 5 minutes or 
slightly longer until bands are discernable.  The image recorded by 
scanning. 
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  Solutions: 
  Detection buffer (DB) 
   Tris 100mM  
   NaCL 100mM  
   Adjust pH to 9.5 
  AP substrate 
   BCIP/NBT   100μl 
   Detection buffer 5ml 
  TBS,10x  
   Tris 24.2g 
   NaCl 80g  
   H2O 800ml. 
    
   Adjust pH to 7.6  
   Add distilled water to final 1L. 
    
   Used at 1x strength. 
   Tween 20 (when required), 0.5ml/L of 1x TBS 
 
 
  2.3.13. ELISA, Indirect method. 
  RMIT ELISA in-house protocol, Walduck Laboratory. 
  Biorad Plate reader 
  96-well plastic microtitre ELISA plate 
   
  Recommended antibody and antigen levels 
   Antibody: 5-15 μg/ml 
   Antigen: up to 20μg/ml 
  Primary antibody: 
   Influenza nucleoprotein, monoclonal, ABD Serotec, 1mg/ml. 
  Secondary antibody (anti species conjugate), ABD Serotec:  
   Anti-mouse antibody conjugated to HRP. 
  Negative control: 
    C. reinhardtii non-transformed strain. 
  Positive control: 
    RMIT Biotech laboratory, Influenza PR8 virus   
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The sample protein (antigen) prepared as described in Protein 
recovery (Method 2.3.9), the protein concentration determined by 
Bradford assay (Method 2.3.10).   
 
  Solutions: 
  Coating buffer (100mls): 
   0.3g sodium carbonate 
   0.6g sodium bicarbonate 
   100mls water 
   pH  9.4 
   Filter sterilized and stored at 4C. 
  PBS buffer (1 litre) 
   Tris 6.05g 
   NaCL 8.76g 
   pH 7.5  
  PBST buffer 
   PBS + 0.05% Tween 20. 
  TMB substrate  
   TMB substrate solutions (x2) brought to room    
   temperature from chiller (30 minutes) and mixed,   
   equal volumes from each of the 2 solutions. Total   
   volume 10mls for 96 well microtitre plate. 
  2M Sulphuric acid. 
 
   2.3.13.1. Optimizing checkerboard ELISA. 
   Antigen (protein).  The initial dilution used was 40μg /ml in 
    coating buffer where 200μl was added to the first row of wells.  
   The number of wells needed was determined by the number of 
   antibody concentrations under study.  Since 6 antibody  
   concentrations were being used then the first row of 6 wells had 
   200μl of antigen added. 
   
Primary antibody.  The initial dilution used was 100μg /ml in 
0.1% milk-powder in PBS. and 200μl was added to first row of 
wells.  The number of wells determined by the number of antigen 
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concentrations under study.  Since 6 antigen concentrations 
were studies then the first row of 6 wells had 200μl of primary 
antibody added. 
   
   Figure 2.3. 
 
   Secondary antibody.  Anti-mouse antibody conjugated to HRP, a 
   1:5,000 diluted in 0.1% milk-powder/PBS.  
 
   Procedure 
   - 100μl of coating buffer (CB) was added to all wells to be 
    used except the first row.  The 200μl antigen sample was 
    added to the first row.  A 100μl multi-tip pipettor was used 
    to transfer 100μl from the first row of wells to the next  
    row.  The added sample and previously added CB volume 
    then mixed carefully, 100μl removed and added to the 
    next row of wells.  The same process was completed for 
    the remaining required antigen dilutions.  The final row of 
    wells had 100μl removed and emptied to waste.  All  
    wells now contained 100μl of serially diluted antigen.  
- After preparing the ELISA plate with antigen (Protein). 
The plate was sealed with a light plastic film and placed 
on a slowly rotating orbital table and incubated at 4C 
overnight.  
   - After incubation, the plate was washed x 4 with PBST 
     buffer, all buffer removed between washes. 
   - 300μl blocking buffer, 1% milk powder, was added to  
    each well and incubated at room temperature for  
    2hrs on a slowly rotating table. 
- Washed, x4 using PBST buffer, with removal of all  
  buffer between washes. 
   - 200μl primary antibody was added to the first row of wells 
    then serially diluted as described for the antigen dilution 
    using a multi-pipettor except the direction of dilution is at 
    90o to the direction of the antigen.  The wells then sealed 
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    with a light plastic film and the plate incubated at 37C for 
    2 hrs. 
   - The plate washed, x4, using PBST buffer, with removal of 
    all buffer between washes. 
   - 100μl secondary antibody added to each well, the plate
    then sealed with a light plastic film and incubated at 37C 
    for 2 hrs. 
   - Washed, x3, in PBST buffer and x1 in PBS buffer for  
    final wash, with removal of all buffer between   
    washes. 
   - 100μl of TMB solution added to each well and   
    incubated for 15 minutes. 
   - 25μl of 2M sulphuric acid added to each well to  
    STOP the TMB reaction.  Well contents change  
    colour from blue to yellow as a consequence. 
   - Results are read using a plate reader at 450nm, usually 
    read within 30 minutes of stopping the TMB reaction. 
   
2.3.13.2. Primary antibody dilution ELISA. 
This procedure is used when a measurement of 
significance is needed to determine the most effective antibody 
concentration to bring about detection of protein of interest 
expression.  
 
The procedure is identical in most respects to the 
optimizing setup described in Method 2.3.13.1 except the plate 
setup for the antigen is different. 
   
The antigen concentration is at a single fixed 
concentration, this concentration was determined from the 
optimizing checkerboard results of 2.3.13.1, although other 
concentrations can be used. 100μl of the antigen concentration, 
in CB buffer, was added to each well. 
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  Figure 2.2. ELISA optimising checkerboard, adapted from  
  the Invitrogen protein website.  Varying the primary antibody  
  concentration in one direction while varying the protein  
concentration in the other direction. 
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   2.3.13.3. Statistical analysis. 
The data obtained from Method 2.3.13.2 was then 
analysed by Chart-pad software to determine the level of 
confidence between the Influenza nucleoprotein expression of 
the transformed and non-transformed C. reinhardtii.  The 
confidence levels are expressed visually as standard error bars 
on the representative graphs.  Any overlapping of error bars 
signifies non-expression at the confidence level being used to 
compare, significance was considered at P<0.001.  Also, the 
hlevels of confidence were considered at 68% (Standard 
Deviation), 95% (2 x SD) and 99.7% (3 x SD). 
 
2.3.14. RNA recovery 
  BioLine, TRIsure, cat no. BIO-38032,100ml. 
 
  Table 2.5. mRNA method flowchart 
 
   As described in the TRIsure protocol with the following  
   modifications: 
 
Homogenization section of the protocol. 
100ml TAP medium, 72hr incubation, Chlamydomonas 
(106/ml) was centrifuged at 2000g for 5 minutes. The cell pellet is 
approx. 700-900mg in weight (wet).  The resultant pellet was re-
suspended in an equal volume of sterile ddH2O and portioned 
into aliquots containing approx. 100-200mg of culture and stored 
at -80C until needed. 
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Table 2.5. mRNA confirmation flowchart 
RNA recovered from C. reinhardtii transformant, DNA removed and cDNA prepared 
for identification. 
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  2.3.15. DNA free RNA preparation.  
  TURBO DNA-free kit, AM 1907, Ambion, Life Technologies 
  Protocol followed as described using the RNA extracted,   
  Method 2.2.14. 
   
The kit described was used to remove contaminating DNA from 
the RNA preparation. 
 
  2.3.16. RT-PCR 
  QIAGEN Omniscript Reverse Transcription kit 
  The protocols were adhered to with the following    
  modifications: 
   
   Trisure extracted RNA was first quantified by Nanodrop  
  spectrophotometry, to provide an estimated RNA level.  The   
  the amount of RNA used for the TURBO DNA-free treatment is  
  required to be less than 200 μg/ml, and the RNA needed for the  
  RT-PCR is required to be between 50ng to 2μg. 
 
  2.3.17. cDNA confirmation 
  DNA electrophoresis, 2.2.6. 
   
   The DNA agarose gel was used to confirm that no DNA was  
  present after DNA removal, TURBO DNA free kit, Method 2.3.15.   
  The agarose gel was also used to confirm the presence of mRNA  
  after RT-PCR.  
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Chapter 3 
 
Construction of vector pBC1  
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3.1. Introduction 
 
 
Figure 3.1. Strategy for pBC1 vector construction.  p463 digest with NcoI 
and PstI enzymes, NP fragment ligated with p463 digest product to construct the 
pBC1 vector. 
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Influenza nucleoprotein (NP) is a protein that is found in 
abundance within the influenza virus particle; NP encases the 
PB1/PB2/PA-  RNP complex, is the most conserved protein in all the 
IVA types and changes very little in response to environmental 
influences.  As well, NP is the type of protein that is mostly targeted by 
the heterosubtypic Influenza immunity mediated by CTL’s.  For these 
reasons NP was the logical choice for the purposes of this study. 
 
 3.1.1. Epitope design 
 
The use of epitopes in vaccine design is a relatively recent 
development, where; 'An epitope is described as that part of an antigen 
that is recognized by the immune system specifically by antibodies, B 
cells and T cells'.  There are Bioinformatic tools that provide epitope 
information for a large array of antigens, and also include data on MHC 
genotype and MHC allele restrictions relating to selected epitope and 
animal model for vaccine efficacy testing.  Bioinformatic tools were 
used in this study to decide on the most immunogenic NP regions to 
include in the NP construct.  The NP design also included the enzyme 
sites NcoI and PstI, and was codon-optimized to be under control of C. 
reinhardtii chloroplast-specific regulatory sequences, PrbcL and TrbcL. 
  
  3.1.2. p463 construction vector 
 
 
The p463 construction vector, provided by the RMIT Algae 
laboratory, is a chloroplast transformation tool that includes an antibiotic 
resistance gene, aadA, flanked by chloroplast-specific regulatory 
sequences, PrbcL and TrbcL. 
 
Ribulose biphosphate carboxylase, 'rbcL', is the most expressed 
of all the chloroplast proteins where the p463 PrbcL and TrbcL regions 
are from within that gene.  The 'aadA' family of genes encode 
aminoglycoside-3″ adenylyltransferases (AAD), that confers resistance 
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to streptomycin and spectinomycin by adenylylation, and originates 
from the R100 plasmid from E. coli.  The aadA gene is a widespread 
antibiotic resistance marker and used in many plant and algal 
transformation studies. 
 
  3.1.3. Chapter experimental aims 
 
 
To design an NP fragment that would stimulate a broad, long 
lasting protective response in an animal model to demonstrate vaccine 
efficacy.  
 
To construct a vector that contains the NP fragment in 
association with chloroplast-specific regulatory sequences PrbcL and 
TrbcL. 
 
 3.2. Results 
 
  3.2.1.  pBC1 construction  
    
   3.2.1.1. NP containing fragment construct 
   The NP sequence was designed to include;  
- The NP sequence that best represented the most 
immunogenic regions of the Influenza nucleoprotein 
gene. 
- To identify the MHC genotype and tailor the epitope 
selection to match the MHC allele restrictions for vaccine 
efficacy testing.  
- Inclusion of the NcoI and PstI enzyme sites with the NP 
sequence.  
- Codon-optimised to be under control of C. reinhardtii 
chloroplast-specific regulatory sequences PrbcL and 
TrbcL. 
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The bioinformatic tools, Syfpeithi, BIMAS, IEDB, 
RankPep, were used to analyse the data.   
    
Table 3.1 
 
The NP sequence forwarded to Genescript for synthesis 
is described;  
 
   Figure 3.2 
   
The synthesized sequence was received from Genescript 
in plasmid pUC57 and transformed into E. coli DH5α. 
 
Subsequent transformed colonies were selected, digested 
with enzymes NcoI and PstI and a gel electrophoresis 
undertaken to confirm the NP sequence size, 332bp.    
  
   Figure 3.3. 
 
The DNA bands displayed in lanes 1 and 2, at ≈332bp, 
confirm the transformation was successful.  The transformed 
colonies selected contained the NP sequence size, 332bp.   
 
The DNA band of 332bp was extracted for ligation.  The 
DNA referred to as the, NP fragment. 
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Table 3.1. 
Summary of findings using; Syfpeithi, BIMAS, IEDB, RankPep, to confirm 
the most immunogenic regions within the Influenza NP protein. 
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Figure 3.2. The designed NP sequence. Using bioinformatic tools, 
Syfpeithi, BIMAS, IEDB, RankPep 
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   3.2.1.2. p463 construction vector 
p463 DNA was recovered and digested with NcoI/PstI 
enzymes.  A gel electrophoresis undertaken to confirm the digest 
product; 2 DNA bands at ≈6.5kbp and ≈0.8kbp were expected 
and obtained. 
 
   Figure 3.4.  
 
The p463 6.5Kbp bands were extracted for ligation.  
  
   3.2.1.3. pBC1 vector construction 
 
The NP 332bp fragment extracted from E.coli DH5α 
transformants, as described in 3.2.1.1, and p463 6.5kbp DNA 
fragment extracted from p463, as described in 3.2.1.2,  were 
ligated and transformation using E.coli DH5α undertaken.  
   
DNA from selected transformants were digested with 
NotI/SacI enzymes and a gel electrophoresis undertaken to 
confirm the digest products. 
 
   Figure 3.5. 
 
The DNA identified in lanes 1 and 3 show the required 
bands, confirming transformation has occurred.  The ≈6.5kbp 
band indicating the p463 DNA size present, as well, the DNA 
band at ≈332bp indicating the NP fragment size.  
    
Confirmation of the NP fragment was undertaken using 
PCR then gel electrophoresis. 
 
   Figure 3.6. 
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          Lane 
                 (bp) 1 2   3      (bp) 
 
   
   
     
 
       2600         
          2838 
 
 
 
                
       332         514  
        339 
               
 
             
   Figure 3.3. pBC1 insert on 1.5% agarose gel.   
   Transformant NcoI/PstI digest products in lanes 1 and 2,  
   following transformation of the NP containing pUC57  
   plasmid and E. coli DH5α. λ-PstI ladder in lane 3.  
   The position of the NP containing fragment, 332bp, 
   (red arrow). 
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                 Lane 
     (bp)  1      2        3     4     5 6       (bp) 
 
    
   
11500 
 6500 
   
   
    
 
      
  
 
 
 
 
 
 
    
 
Figure 3.4.  p463 digest on 1.5% agarose gel.  
    p463 NcoI/PstI digest products after digestion.  
   Lanes 1 and 2, contain the required 6.5kbp fragment 
   (red arrow).  Undigested DNA in lanes 3 and 4. 
    λ-PstI ladder in lanes 3 and 4. 
 
 
 
 
 
 
    
   
 
 
 
  
5077 
805 
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   Figure 3.5. pBC1 vector on 1.5% agarose gel. 
   Transformant NcoI/PstI digest products following   
   transformation of pBC1 insert and p463, Lanes 1  
and 3, NP fragment, 332bp (red arrow). 
    λ-PstI ladder, Lane 5. 
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       Lane 
(bp)   1  2  (bp) 
 
 
   
 
 
 
 
 
 
 
           514 
                           332    
    
           264 
 
   
 
   
    Figure 3.6. PCR of pBC1 vector  
on 1.5% agarose gel. PCR confirmation 
of transformant containing NP epitope.  
Lane 2, 332bp NP containing fragment 
(red arrow).  
    λ-PstI ladder, lane 1.  
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 3.3. Summary 
 
Construction of vector pBC1 was necessary to enable integration 
of the NP fragment with the chloroplast-specific regulatory sequences, 
PrbcL and TrbcL. 
 
Design of the NP epitope was completed using bioinformatics 
tools to include; the most immunogenic regions within the NP gene, 
MHC genotype and allele restricton considerations vaccine efficacy 
testing, and be codon-optimized to be under control of the C. reinhardtii 
chloroplast-specific regulatory sequences, PrbcL and TrbcL. 
 
The synthesized NP fragment was transformed into p463 to 
integrate with the chloroplast-specific regulatory sequences, PrbcL and 
TrbcL.  The NP fragment was ligated into the extracted 'aadA' 
resistance region of p463. 
 
  The vector, pBC1, was constructed successfully.    
 
  Corollary 
 A  further vector, pBC2, was constructed to the same 
completeness as pBC1.  This vector also included the chloroplast 
regulatory sequences PrbcL and TrbcL but differed with respect to the 
NP design.  The NP fragment included an adjuvant, referred to a 
Bovine lumazine synthase (BLS).  BLS was added to enhance T-cell 
immune response to the NP fragment during vaccine efficacy testing. 
 
   Prbcl-NP_BLS-Trbcl 
 
Unfortunately, due to time restraints, pBC2 was not taken further. 
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Chapter 4 
pBC1+ vector construction 
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 4.1. Introduction 
 
 
  
 
Figure 4.1. Strategy for construction of pBC1+ expression vector. 
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The previously constructed pBC1 vector required an antibiotic 
resistance marker, aadA, added to confer resistance to spectinomycin.  
The aadA resistance marker is necessary to enable selection of 
plastomic transformants.  The new vector constructed is referred to as 
pBC1+. 
   
4.1.1.  pBC1+ insert construct 
 
To add the spectinomycin resistance, pBC1 is required to be 
modified to include 2 additional enzyme sites, NotI and SacI.  This is 
achieved by PCR amplification of the PrbcL–NP–TrbcL containing 
expression cassette BC1, using oligonucleotides; 
 
OID25  
(forward, 5_-gtgatccgcggccgcatgggtttataggtattttgagacc-3_)  
OID26 
(reverse, 5_-gtgatccgagctcgtatgttactatttcttttattacttataaaatataatac-3_) 
 
Designed to add the NotI enzyme site at the 5' end of PrbcL and 
the SacI site at the 3' end of TrbcL.  The 1.2 kb PCR fragment then 
isolated and digested with NotI/SacI to be inserted into the 
corresponding sites (NotI/SacI) of p463 and p463+5A vectors. 
  
4.1.2. pBC1+ vector construct 
 
Both vectors p463+5A and p463 contained the required aadA 
antibiotic marker, however, p463+5A, unlike p463, contained a coding 
region of gene of interest CTB-WNV under control of PrbcL and TrbcL 
regulatory sequences.  This expression cassette was to be removed by 
NotI/SacI digestion and the resulting vector used for the insertion of 
pBC1 expression cassette.  The pBC1 expression cassette would be 
inserted in the 3’ end of TrbcL of p463, where the NotI/SacI sites are 
located.  
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4.1.3. Chapter experimental aims 
To construct pBC1+ vector containing the pBC1 expression 
cassette and aadA antibiotic resistance marker. 
 
 4.2. Results  
  
  4.2.1. pBC1+ insert preparation 
   PrbcL–NP–TrbcL PCR fragment from pBC1 was amplified  
  using a set of two primers; 
 
OID25  
  (forward, 5_-gtgatccgcggccgcatgggtttataggtattttgagacc-3_)  
OID26 
(reverse,5_gtgatccgagctcgtatgttactatttcttttattacttataaaatataatac-
3_) 
 
The DNA was recovered and digested with NotI/SacI enzymes.  
A gel electrophoresis was undertaken to demonstrate the expected size 
increase, from 332bp to 1.2kbp, confirming the PrbcL_NP_TrbcL 
fragment.  The fragment was extracted for ligation with p463+5a and 
p463 vectors. 
    
  Figure 4.2.  
   
  4.2.2. pBC1+ vector preparation. 
The p463+5A vector was digested with NotI and SacI enzymes, 
a gel electrophoresis undertaken and the 6.5kbp DNA extracted.  
 
  Figure 4.3. 
 
  4.2.3. pBC1+ vector construction 
Ligation with p463+5A proved to be easier, this vector only was 
used for pBC1+ construction. 
 
Influenza nucleoprotein expression in microalgae, B. Cooke 
87 
pBC1+ insert, 1.2kbp DNA (4.2.1) and p463+5A, 6.5kb DNA 
fragment (4.2.2) were ligated.  The subsequent transformants were 
digested with NotI/SacI to confirm the presence of the 6.5 kb and 1.2 kb 
fragments, the fragments being the vector backbone and PrbcL–NP–
TrbcL respectively. 
Figure 4.4. 
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   Figure 4.2. PCR NotI/SacI digest  
   on 1.5% agarose.  PCR digest 
    product (red arrow) at 1.2kbp, Lane 2. 
   λ-PstI ladder, lane 1. 
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        Lanes 
      
    (bp)            1       3       4  6     7      8  
 
  
    
  
   
   
  
 
 
 
    
  1159 
  
             
 
 
    
    
   
 
 
 
Figure 4.3.  p463+5a vectorNotI/SacI digest on  
  1.5% agarose.  Digest bands at 6.5kbp and 1.6kbp 
  (arrows).  The required DNA band located at 6.5kbp,  
  lanes 6, 7 and 8 (red arrow).  
  λ-PstI ladder lane 1. 
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Figure 4.4. Transformant NotI/SacI  
    digest products, on 1.5% agarose.  
    Transformants in lanes 2 and 3, digest  
    bands at 6.5kbp and 1.2kbp. 
    λ-PstI ladder lane 1.  
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  4.2.4. pBC1+ confirmation 
 
pBC1+ transformants were confirmed to contain the NP 
sequence by PCR.  PCR NP primers being; 
 
    FWD 5’… GGT TTA TAT TCA ATG TGT ACA G, 22bp. 
    REV 5’… CGA AAT GGA TCA ATA CCA AC, 20bp. 
 
Upon completion of PCR, a gel electrophoresis was undertaken 
of the product.  The gel confirming the constructed pBC1+ vector 
contains the NP sequence size, 332bp. 
 
  Figure 4.5.  
 
To confirm the introduction of the PrbcL–NP–TrbcL expression 
cassette into p463-5a vector, BC1+ was sequenced. Resulting 
sequence confirmed the PrbcL–NP–TrbcL sequence was not modified 
and was present. 
 
  Figure 4.6. 
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Lane 
       (bp)        1     2         3                 (bp) 
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          332 
      339             
      264 
            
            
 
 
 
   
Figure, 4.5. pBC1+ vector transformant PCR  
  product on 1.5% agarose. Confirming the 332bp  
  NP fragment, lanes 2 and 3 (red arrow).  
  λ-PstI ladder, lane 1. 
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Figure 4.5. Sequencing confirmation of expression cassette in 
pBC1+ construction. 
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4.3. Summary 
 
pBC1+ expression vector was constructed to contain; PrbcL–NP–TrbcL, 
the selectable spectinomycin resistance marker PrbcL–aadA–TrbcL and the 
tscA gene for homological recombination into chloroplast DNA.  
 
The pBC1+ vector construction was confirmed; by restriction digestion 
patter, by PCR and by sequencing.  These strategies demonstrated the 
expression vector was constructed for the transformation of the C. reinhardtii 
chloroplast DNA. 
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Chapter 5 
Transformation of C. reinhardtii  
chloroplast genome 
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5.1. Introduction 
 
  
 
 
Figure 5.1. Intended location of pBC1+ in the C. reinhardtii genome. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Influenza nucleoprotein expression in microalgae, B. Cooke 
97 
Microalgae, moreso Chlamydomonas reinhardtii (CC124), have 
been the subject of considerable investigation where research has 
served to highlight their potential as expression vehicles of foreign 
protein.  Consequently, C. reinhardtii has the most advanced molecular 
genetic toolkit developed for any of the microalgae. All three 
genomes—nuclear, chloroplast and mitochondrial—have been 
sequenced, with transformation protocols and vectors available for 
each genome.   
 
In this study chloroplast transformation was chosen as the route 
to integrate the influenza NP into C. reinhardtii, where research has 
shown chloroplast transformation through homologous transformation 
occurs quite successfully.  Transformations using foreign DNA can be 
precisely targeted to any region in the chloroplast genome that contains 
a so-called “silent site” for transgene integration.  Also, chloroplast 
transformation is able to offer stable expression where expression 
levels of protein accumulation, typically 1–10 % of total protein, have 
been reported. 
 
One such option to integrate foreign genes into the chloroplast is 
through the use of the 'rbcl', ribulose diphosphate carboxylase enzyme, 
site where the 'rbcl regions' are combined with the foreign gene 
beforehand, as was used in this study.  When transformation with C. 
reinhardtii takes place the introduced 'rbcl' regions combine into the 
gene encoding the highly-expressed photosystem I ribulose 
biphosphate carboxylase subunit, so integrating the foreign gene.  The 
foreign gene in this study being the influenza NP epitope.   
 
5.1.1. Chloroplast genome transformation 
 
The transformation technique of choice for microalgae 
chloroplast genome transformation has been with the use of biolistics, 
as used in this work. The gene gun was used to bombard a lawn of 
standardized C. reinhardtii cells on the surface of an agar medium with 
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micron-sized gold particles carrying the pBC1+ DNA.  The biolistic 
technique allows the delivery of transforming foreign DNA directly into 
the chloroplast through the cell wall and at least three membranes 
where the DNA integrates by recombination into the plastid genome of 
the Chlamydomonas.   
 
The bombarded C. reinhardtii are then transferred and incubated 
on spectinomycin containing agar for up to 2 weeks for transformants to 
appear.  The transformants are then confirmed to contain the foreign 
fragment (NP in this instance) then foreign (NP) protein expression 
evaluated. 
 
  
  5.1.2. Chapter experimental aims 
 
 
To transform C. reinhardtii chloroplast with the previously 
constructed pBC1+ plasmid and then confirm expression of the 
Influenza NP fragment.   
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5.2. Results 
  5.2.1. pBC1 + and C. reinhardtii transformation 
    
 pBC1+ vector and C. reinhardtii DNA were recovered and 
transformation undertaken.  Transformants were selected based on 
their ability to grow on the spectinomycin containing TAP medium.  
    
  Figure, 5.2. 
  
A multi-well plate containing TAP broth + spectinomycin was 
also used during the selective process.  The plate was used to screen 
putative transformants grown on TAP + spectomycin plates 
demonstrated in FIgure 5.2.  In this instance, growth in the near center 
dark well indicates a transgenic transformant. The light green growth in 
other wells is indicative of reduced ability to grow in the spectinomycin 
containing medium, demonstrating possibly an ineffective and unstable 
transformant. 
   
Figure, 5.3. 
     
Further screening was undertaken of the putative transformants 
to confirm their transgenic nature, being stable antibiotic inclusion, by 
inoculating further TAP + spectinomycin agar medium over successive 
re-growth cycles. 
 
Figure, 5.4. 
     
 A total of 10 separate transformations were completed; 7 
transgenic transformants were recovered that exhibited stable growth 
over successive re-growth cycles in spectinomycin containing TAP 
medium. 
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Figure 5.2. Putative C. reinhardtii growth after 
transformation. pBC1+ DNA and C. reinhardtii 
putative transformants after 3 days at 25oC in 24hr 
light on TAP medium containing spectinomycin 
antibiotic. 
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   Transgenic negative, although slight growth 
 
 
 
   
  
 
 
 
 
 
 
 
   
   Potential transgenic C. reinhardtii 
 
 Figure 5.3. Putative C. reinhardtii TAP broth growth after 
 transformation. C. reinhardtii putative transformant growth in broth   
culture after 3 days at 25oC in 24hr light in TAP medium containing 
 spectinomycin antibiotic.  Potential transgenic transformant in center   
well (red arrow). 
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           Transgenic   
         C. reinhardtii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 5.4. Transgenic C. reinhardtii on TAP agar  
  containing spectinomycin antibiotic. Potential  
transgenic C. reinhardtii, after successive re-growth  
cycles on TAP + spectinomycin agar (red arrow).   
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5.2.2. NP DNA integration and expression 
confirmation. 
 
DNA was recovered from transgenic transformants and a PCR 
and gel electrophoresis were undertaken to determine the presence of 
the Influenza NP fragment, to demonstrate the NP fragment size, 332 
bp. 
 
  Figure 5.5. 
 
   The PCR DNA was prepared and forwarded for   
   sequencing. 
    
  Figure 5.6. 
 
   The sequencing results were aligned using the NCBI site,  
  confirming the NP sequence was present in C. reinhardtii. 
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   Figure, 5.5. pBC1+ and C. reinhardtii 
   transformants T7 and T8 PCR product  
   on 1.5% agarose. NP fragments shown  
   in lanes 3 and 4, 332bp.  
   BL 1kbp ladder, lane 1. 
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 Figure 5.6. C. reinhardtii transformant, T8, sequencing results.  
 Confirming the presence of Influenza NP fragment in C. reinhardtii. 
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  5.2.3. Transcription of NP transgene 
    
   5.2.3.1. RNA analysis 
   Method, 2.3.14. 
   C. reinhardtii transformant, T7 
 
 A gel electrophoresis was completed both before and 
after DNA removal to check the efficiency of DNA removal, as 
well, a PCR was undertaken to detect for contaminating DNA at 
332bp. 
 
   Figure, 5.7.  
 
 RNA spectrophotometry at 260nm (Nanodrop) was used 
to determine the RNA concentration to be used for RT-PCR.   
     
   5.2.3.2. RT-PCR 
   Method, 2.3.16. 
 
   The method was followed as per kit instructions. 
 
   5.2.3.3. cDNA electrophoresis 
C. reinhardtii transformant, T7, and C. reinhardtii WT (Negative 
control)  
 
 The presence of cDNA was checked by gel 
electrophoresis.   
 
   Figure, 5.8.    
 
 The presence of cDNA confirms mRNA was produced by 
the C. reinhardtii T7 transformant for the Influenza NP protein. 
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      Lane 
    (bp)  1 2    3        4   5  (bp) 
 
 
 
 
 
 
   
         DNA 
     400                            
     
     200       
   
 
 
     
     Before DNA removal 
       (bp)  1   2    3 
  
 
 
 
 
 
 
 
 
 
 
 
     
       After DNA removal 
Figure 5.7.  RT-PCR of RNA extract before and after DNA removal. The 
presence of DNA before DNA removal and removal of DNA after treatment. Lanes 
2,3,4,5 BEFORE; Lanes 2,3 AFTER. Bioline 1kbp marker, Lane 1. 
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 400             332 
 
 
 200 
 
 
   
  Figure 5.8. Electrophoresis of RT-PCR product  
  on 1.5% agarose. Negative control in lanes 2 and 3. 
  Transformant (T7) in Lane 5 indicating the presence 
  cDNA , 332bp (red arrow).  
  Bioline 1Kbp hyperladder, Lane 1. 
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  5.2.4. Protein expression 
     
   5.2.4.1. Protein analysis  
Protein recovery yield was dependent upon method of 
extraction, the yield was best using the recovery procedures 
SDS/NaOH or Tris/SDS, both procedures required grinding in 
liquid nitrogen.  The protein yield averaged between 80mg-
90mg/109 cells wet weight compared well to the reported 
70mg/109 cells. 
    
   Figure 5.9. 
 
 A protein standard curve from which the protein recovery 
yields were compared, for the various C. reinhardtii 
recombinants.  
    
   Figure, 5.10. 
    
 The recovered proteins were visualized on an SDS 
PAGE.    
The protein band evident at 50kDa indicates the presence 
of the rubisco protein subunit, signifying the chloroplast envelope 
has been broken into by the protein extraction procedure and the 
protein bands evident between 10kDa and 15kDa indicate the 
protein extraction process wasn't affecting the recovery of small 
proteins.  This is important since the expressed NP protein has a 
predicted size of 13kDa. 
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  Figure 5.9. Protein standard curve.   
  The trend curve used to compare protein  
  recovery from various C. reinhardtii protein  
  extractions used.  
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Figure 5.10. C. reinhardtii transformants protein SDS page. Protein recovered 
for selected transformants, T8 (lanes 2 to 4) and T7 (lanes 5-8).  Protein bands of 
interest between 10kDa and 15kDa for all lanes.  Unstained ladder, lane 1. 
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   5.2.4.2. Western blot 
   C. reinhardtii T8 transformant. 
   Negative control, C. reinhardtii WT 
   Positive control, RMIT Biotech laboratory, Influenza PR8  
   virus protein extract. 
 
    Despite undertaking 8 Western blots, detection of  
   NP expression was not obtained.  Various variations of the  
   procedure were trialed including chemi-luminesence   
   detection, with no success. 
 
   5.2.4.3. ELISA 
   C. reinhardtii T8 transformant  
   Negative control, C. reinhardtii WT 
   Positive control, RMIT Biotech laboratory, Influenza PR8  
   virus protein extract. 
 
The protein and antibody concentrations were based on 
those recommended: 
   - Protein antigen, up to 20μg/ml. 
   - Primary antibody, between 5-15μg/ml. 
 
An exploratory ELISA was completed first using an 
Optimizing Checkerboard.  C. reinhardtii T8 transformant protein 
only was used, no negative control was included. 
    
Figure 5.11. 
    
Of interest, the most effective concentrations in detecting 
NP expression of transformant T8 were; 
   - Protein,12.5- 25μg/ml 
   - Antibody, 12.5μg/ml 
    
    A primary antibody dilution ELISA was next undertaken. 
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C. reinhardtii transformant T8 protein was determined by 
the concentration found effective in the Checkerboard ELISA, 
the concentration selected was 15mg/ml.  The negative control 
was at the same concentration, 15mg/ml. 
 
The primary antibody concentrations were varied outside 
the recommended levels for an ELISA but included the 
concentrations found to be most effective in the checkerboard 
ELISA; the concentrations being, 6.25 to 25μg/ml. 
 
   Figure 5.12. 
 
The standard error was subsequently calculated for each 
antibody concentration for the T8 transformant and the negative 
control.  The standard errors are displayed as error bars on the 
graphs using Graph-Pad.  The significance of difference 
between transformant and negative control was found to be 
highly significant, P<0.001, indicating NP expression had 
occurred. 
 
Other antibody concentrations were also compared but 
were discounted since the absorbance was either too low or too 
high, high absorbance is normally associated with high 
background signal.  The discounted levels were also outside the 
recommended ELISA limits.  
 
Of interest, the concentrations of primary antibody found 
to be most effective in detecting NP expression support those 
found in the Checkerboard ELISA, being 6.25 μg/ml to 
12.5μg/ml. 
 
A further transformant, T7, was also selected to confirm 
NP expression.  The selection was based on the viewed protein 
recovery profile in the 10kDa to15kDa range on an SDS-PAGE.  
The procedures for protein recovery and protein expression 
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confirmation by ELISA were identical to those used for 
Chlamydomonas transformant T8. 
 
   Refer Figure 5.13. 
 
The results found for transformant T7 were very similar to 
those for transformant T8; being 6.25 μg/ml to 12.5μg/ml, being 
the most effective antibody concentrations in detecting the NP 
expression. 
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Figure  5.11. ELISA optimizing checkerboard.  T8 transformant  
protein (antigen) and NP antibody concentrations were serially diluted  
in a single 96 well plate to indicate an optimum concentration that 
maximized the detection of NP expression.   
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 Figure 5.12. Transformant T8, ELISA NP antibody 
 dilution assay.  The NP antibody dilution serially diluted  
 and assayed against a known T8 protein antigen concentration, 
15μg/ml.  Negative control, C. reinhardtii WT.  
Standard error calculated for each antibody concentration  
and significance of expression compared. 
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Figure 5.13. Transformant, T7, ELISA NP antibody  
dilution assay.  The NP antibody dilution serially diluted  
 and assayed against a known T7 protein antigen concentration, 
15μg/ml.  Negative control, C. reinhardtii WT.  
Standard error calculated for each antibody concentration  
and significance of expression compared. 
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5.3. Summary 
 
 Transforming C. reinhardtii required a biolistic technique to introduce pBC1+ 
DNA into the C. reinhardtii chloroplast, the procedure for achieving this is well 
documented.  The 7 transgenic C. reinhardtii transformants obtained all exhibiting 
stable growth in an antibiotic containing environment over extended cultivation and 
regrowth cycles. 
 
Not all the seven C. reinhardtii transformants were checked for the presence 
of the NP fragment.  Of the two that were, both were confirmed positive by PCR to 
have the required NP fragment and one was further confirmed by sequencing. 
 
An RT-PCR was undertaken on one of the transformants, where the cDNA 
recovered confirmed the presence of mRNA for the influenza NP fragment.   
 
Two of the 7 C. reinhardtii transformants were studied by ELISA, T7 and T8, to 
confirm influenza nucleoprotein expression.  Both were found to express the NP 
protein.   
 
  Unfortuantely, the Wester Blot failed to confirm the ELISA expression. 
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Chapter 6 
 
General Discussion 
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The main reservoir for the spread of Avian Influenza virus to man is through 
wild bird populations (Costa et al., 2010; Gilbert et al., 2013; Munster and Fouchier, 
2009); the sometimes close association wild birds have with domesticated birds and 
poultry provides Influenza with a direct path to seriously implicate man and other 
animals (Pantin-Jackwood et al., 2014; Hamilton et al., 2009).  The association of 
AIV with domesticated birds and poultry instigates significant destruction of flocks, 
causing economic hardship particularly for those that depend on them for food and 
income (Kapczynski et al., 2013; Burns et al., 2013; Wainwright et al., 2012).  The 
production of AIV vaccines for this industry has always been a significant priority, it is 
considered by breaking the IV infectious cycle at the domestic bird stage a significant 
step forward to controlling the impact of Influenza on man would be realized.  
 
Development of AIV vaccines have mostly focused on the 2 major surface 
proteins haemagglutinin and neuraminidase, however, the natural variation that 
occurs with both these proteins, through antigenic drift and shift, has made 
constructing a definitive vaccine to control Influenza very difficult (Boon et al., 2009; 
Bouvier and Lowen, 2010).  As a consequence, constructing likely vaccine 
candidates against internal Influenza proteins that are not subjected to the same 
antigenic drift and shift, namely, the more conserved proteins; NP, M1 and M2 has 
and is being intensely researched (Stoloff and Caparros-Wanderley, 2007; Lee et al., 
2014; Toussaint et al., 2011).  Although the more conserved IV proteins don't elicit 
the same humoral antibody immune response as the IV surface proteins, their 
potential to be associated with rapid, long-lasting, morbidity associated cellular 
immune response, moreso T-cell, has long been recognized (Lillie et al., 2012; Liu et 
al., 2013; Powell et al., 2013).  
 
This study was aimed at exploring cellular immunity, to investigate the T-cell 
immunogenicity of an IV NP peptide vaccine for the poultry industry. 
  
 T-cell peptide vaccines are based on a chemical approach to synthesize 
identified epitope fragments that are highly immunogenic and can be tailored to 
produce the desired immunogenic responses (Jacob et al., 1985; de Groot et al., 
2010; Gorbalenya et al., 2010).  However, peptide vaccines have several 
disadvantages including the limitations conferred by major histocompatibility complex 
(MHC) restriction and poor immunogenicity, in some instances there is a need for 
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carrier molecules to add chemical stability and to adjuvant for a robust immune 
response (Bijker et al., 2007; Ichihashi et al., 2011; Li et al., 2014; Li et al., 2012).  
Using conventional methodologies, identification or recognition of immunodominant 
epitope fragments is difficult to near impossible since one of the key issues in T-cell 
epitope prediction is identification of the MHC binding.  MHCs are among the most 
polymorphic proteins in higher vertebrates, with more than 6000 class I and class II 
MHC molecules listed (Robinson et al., 2015).  Determining the peptide-binding 
preferences exhibited by this extensive set of alleles is also beyond the present 
capacity of experimental techniques, consequently the development and application 
of bioinformatic prediction methodologies presented itself to be a much-needed 
alternative (Brusic et al., 2004; Gorbalenya et al., 2010).  
 The use of such bioinformatic methodology was utilized in this study, to select 
an AIV NP epitope that bought about a cellular immune response best suiting a 
mouse model to confirm vaccine immunogenicity.  Also, some important design 
features were added; the NP fragment was required to contain, in addition to the NP 
epitope, 2 enzyme sites and be codon optimized.  Both features were important 
inclusions for subsequent transformation events (Dressen et al., 2009).  
 The cost and method of vaccine application is another significant hurdle for 
many stakeholders particularly those in the Asian poultry industry where thousands 
of birds may require to be vaccinated, and that's just in 1 farming community (Burn et 
al., 2013).  To many in the developed world, in-ovo and intramuscular injection 
vaccination are fait accompli, in the Asian and under-developed world they are too 
costly and impractical for their widespread mostly smaller stakeholders (Hamilton et 
al., 2013; Peiris and Yen, 2014).  To address these concerns this study selected the 
oral route for IV vaccination (Rosales-Mendoza et al., 2012), with the intention of 
combining an immunodominant IV NP epitope with a stable food-stock.  Also, oral 
route vaccination would associate the IV NP vaccine with mucosal immunity, the 
most active and evolved of all animal immune responses (van Riet et al., 2012).  
 One such direction for the oral presentation of vaccines has been with the use 
of plants (Mishra et al., 2008; Xu et al., 2011), and in particular the use of microalgae 
(Franklin and Mayfield, 2005; Potvin and Zhang, 2010).  The advantages of 
microalgae as a stable food-stock for oral vaccine presentation was highlighted by 
Dressen et al., 2009), accordingly, microalgae were considered the best option for 
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this study.  Of all the microalgae, C. reinhardtii has been the most studied with a 
large mutant collection available (Kindle and Sodeinde, 1994; Neupert et al., 2012; 
Popescu and Lee, 2007).  It was upon reviewing research associated with C. 
reinhardtii nuclear and chloroplast transformation that the chloroplast was selected to 
be the expresser of the AIV NP fragment protein for this work (Eberhard et al., 2002; 
Specht et al., 2010; Gong et al., 2011).   
 It should be emphasized however, although the algal chloroplast is favored for 
foreign gene expression, chloroplast expression does suffer from low yields.  It has 
been reported that gene expression in the chloroplast is tightly regulated at the 
translational level (Eberhard et al., 2002).  Mayfield (2007) also noted this inefficiency 
in chloroplast transgene expression, they found the type of promoter and UTRs can 
have an effect in reducing the problem.  However, Surzycki (2009) considered 
promoter and UTRs weren't the only factors that affect expression levels, the site of 
integration in the chloroplast, as well as accompanying random integration events in 
the nucleus, may also have an affect.  
In this study, in order to transform the chloroplast of C. reinhardtii with an IV 
NP fragment a suitable NP expression vehicle was required to be constructed before 
C. reinhardtii could be transformed.  
 
Firstly, it was necessary to transform the NP fragment into a construction 
plasmid to include a chloroplast promoter to achieve NP expression in C. reinhardtii.  
By far the most utilized vehicle for the transformation of plants and microalgae for this 
purpose has been the use of markers that confer resistance to antibiotics (Cerutti et 
al., 1997; Goldschmidt-Clermont, 1991).  The antibiotic marker is a bacterial-sourced 
aadA gene that provides resistance to spectinomycin and streptomycin.  Indeed, 
many of the 50 successful foreign gene implants into the chloroplasts of algae have 
been with the use of cassettes containing an antibiotic marker (Purton et al., 2012), 
however, the use of antibiotic makers for transformation has its critics.  There are 
concerns that integration of antibiotic resistance raises environmental and health 
concerns, although there are strategies for excision of such marker genes after 
transformation (Lossi and Waheed, 2011).  Also, there have been several 
unsuccessful transformation studies reported that serve to illustrate that while 
antibiotic markers have proved useful for selective purposes and gene-disruption 
 
Influenza nucleoprotein expression in microalgae, B. Cooke 
123 
experiments, the level of recombinant protein being expressed was quite low and 
difficult to quantify (Franklin and Mayfield, 2004).  
 
 In this work, an antibiotic marker cassette was used for performing the 
necessary transformation events, the cassette utilized referred to as the p463 
plasmid.  The p463 plasmid cassette included an aadA antibiotic resistant gene 
flanked by a chloroplast PrbcL and TrbcL (Dressen et al., 2009).  Although other 
chloroplast promoters have been used by researchers, atpA and psbA genes in 
particular (Griesbeck et al., 2006; Klein et al., 1994; Mayfield et al., 2007), rbcl 
(ribulose biphosphate carboxylase large subunit) was selected because of its 
association with the most expressed region in C. reinhardtii, the photosystem, and 
has been used successfully before (Dressen et al., 2009; Marcos, 2013).  In this 
work, using traditional transformation procedures, the aadA gene of p463 was 
excised and successfully replaced with the IV NP fragment, the developed construct 
now including the NP segment flanked by an rbcl promoter and terminator; 
PrbcL_NP_TrbcL.  
Secondly, since the NP fragment replaced the aadA gene in the p463 
construction cassette, an aadA gene was needed to be re-introduced to enable 
identification of the NP transformants upon transformation of C. reinhardtii.  This 
study used 2 such construction plasmids for this task; p463 and p463+5a; the 
p463+5a cassette was previously constructed by Marcos (2015).  Problems were 
encountered obtaining suitable transformants with p463, although transformants 
recovered demonstrated antibiotic resistance to spectinomycin, upon digestion, the 
size of the DNA that had been transformed was larger than that predicted.  Further 
study could have explained this effect, however, since the DNA size increase may 
have had a negative effect on achieving the final goal of this work p463 was not 
continued with.  Subsequent transformation with p463+5a proved to be easier and 
successful, upon digestion of the DNA from transformants obtained, DNA of the 
predicted size was obtained.  The problems associated with adding the aadA marker 
to the PrbcL_NP_TrbcL construct reflects the previously referred to transformant 
inefficiency associated with some foreign implants when using this marker.   
 
The new IV NP containing construct, pBC1+, now included the aadA antibiotic 
marker; Prbcl_NP_Trbcl_aadA.   
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 Finally, the expanded construct, Prbcl_NP_Trbcl_aadA, was now ready to be 
transformed into the chloroplast of C. reinhardtii.  Of the ten subsequent 
transformations completed, seven transgenic C. reinhardtii were recovered.  The low 
recovery of transgenic C. reinhardtii was expected even though DNA biolistic 
bombardment was used.  The foreign DNA was required to be forced through not 
only the C. reinhardtii cell wall but also the chloroplast outer membranes, and then to 
be incorporated into the chloroplast genomes (Boynton et al., 1988).  It is a feature of 
chloroplast transformation for the recovery of low numbers of transformants, Day 
(2011) found the transformation process not very efficient, they reported transformed 
Chlamydomonas cells appeared with a frequency of approximately 10-
5
.   
 Upon C. reinhardtii transformation numerous putative transformant colonies 
were observed initially, the failure of the majority to continue their growth upon being 
re-inoculated onto and into spectinomycin containing media may have been due to 
the implanted DNA not being incorporated into the chloroplast genomes, existing as 
non-replicating DNA or perhaps being included but in an ineffective orientation.  To 
confirm the transgenic uptake of the Prbcl_NP_Trbcl_aadA segment in C. reinhardtii, 
stable antibiotic resistance is required to be demonstrated over successive regrowth 
cycles, normally up to 10 cycles (Neupert et al., 2012; Eichler-Stahlberg et al., 2009); 
this was achieved for the 7 transformants obtained in this study.  
The next requirement was to demonstrate the presence of the NP fragment in 
the transgenic C. reinhardtii.  There are a variety of methods available for DNA 
recovery, those considered applicable were evaluated for their effectiveness where 
CTAB/PEG proved to be the best.  The DNA subsequently recovered from the C. 
reinhardtii transformants were confirmed to contain the IV NP fragment using 
conventional confirmation procedures; gel electrophoresis, PCR and sequencing.  
 
Confirmation of NP protein expression in C. reinhardtii posed a more complex 
task requiring initial confirmation of mRNA, mRNA being the essential precursor for 
subsequent protein expression.  Using a combination of commercial extraction 
protocols the total RNA was extracted from a C. reinhardtii transformant, DNA 
removed and cDNA prepared using RT-PCR.  The resultant mRNA product was 
clearly present, as visualized by gel electrophoresis, the correct band size for the NP 
 
Influenza nucleoprotein expression in microalgae, B. Cooke 
125 
fragment displayed at 332bp, confirming that mRNA for the IV NP protein was being 
produced.  
 
 There are numerous methods available for protein extraction from C. 
reinhardtii, the major need for this study was that the extraction method had to not 
only break open the chloroplast compartment but be proficient in recovering an 
expressed small sized protein, NP at 13kda, and being able to recover enough 
protein if expression was low.  The aadA maker transformation approach as used in 
this work can be associated with low levels of expression (Franklin and Mayfield, 
2005; Wannathong et al., 2016; Chen and Melis, 2013).   
 
 Of the protein extraction methods considered there were 2 methods that 
performed well when compared after measuring total protein extracted and 
subsequent viewing using a variety of SDS-PAGE formulations.  The best small 
protein separation was obtained using a procedure that is designed for 
demonstrating small proteins since the NP protein was of a size that could easily be 
caught in the clutter that tends to fill the bottom of a normal SDS PAGE when running 
whole cell lysates of Chlamydomonas.  The protein extraction method demonstrated 
small size protein recovery from the C. reinhardtii chloroplasts, as well, the rubisco 
subunit was clearly evident at 50kDa on the SDS PAGE.  The presence of the 
rubisco subunit, one of the main proteins expressed in the chloroplast, indicated the 
effectiveness of extraction procedures used in disrupting the chloroplast and 
releasing the chloroplast proteins (Day and Goldschmidt-Clermont, 2011; Wang and 
Kolattukudy, 1996).  
 
 Confirmation of NP protein expression in the protein extracted from transgenic 
C. reinhardtii was evaluated using both Western blot and ELISA.  
 
 Expression confirmation by WB was first considered, unfortunately WB failed 
to detect expression of the NP protein.  Similar difficulties have been found by other 
researchers with some of their constructs (Coragliotti et al., 2011; Mayfield and 
Franklin, 2005), they also detected mRNA but no product expression using WB.  
Coragliotti (2011) found translation of their three chimeric mRNAs was greatly 
reduced when compared to endogenous mRNAs under control of the same atpA 
promoter/UTR.  Their results pointed to translation as the main step limiting the 
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expression of heterologous proteins in the C. reinhardtii chloroplast.  Rasala (2013), 
Mayfield (2007) and others have sometimes found a poor correlation between mRNA 
accumulation and protein accumulation, as has been reported for endogenous 
chloroplast genes.  Eberhard (2002), Nickelsen (2012) reported stable accumulation 
of recombinant mRNAs but no protein accumulation could be detected.  Rasala 
(2010) incorporated the use of FLAG epitopes attached to the C terminal end of each 
protein sequence in the expression of seven human proteins in the chloroplast of C. 
reinhardtii and ran anti-FLAG WB, a must for detecting low expression.  They 
demonstrated highly variable expression levels, indicating that protein yields depend 
primarily on the intrinsic properties of each protein expressed.  There are questions 
that have been asked on the validity of WB in some situations (Taylor et al., 2013).   
 Although there are numerous reports showing the inefficiency of C. reinhardtii 
foreign protein expression, as has been described, there certainly have been 
successes.  Accordingly, in the current study, since limited WB optimization was 
undertaken, lack of WB expression detection may have been due to primary antibody 
selection and antibody concentration used.  Both antibody selection and antibody 
concentration are currently being further investigated. 
The indirect ELISA was also implemented in this work to confirm NP 
expression in C. reinhardtii.  The ELISA is a very sensitive procedure and is 
commonly used for both confirming and quantifying protein expression.  Hou (2012), 
Kodihalli (2000), Lim (2013) used ELISA to confirm NP expression for their vaccines, 
although a non-algal direction was taken with their work.  In this study, using well 
established protocols the conditions for the ELISA were first optimized to establish 
the levels where antigen (NP protein) and primary antibody were at their most 
reactive then an antibody dilution ELISA was undertaken to establish C. reinhardtii 
transformant NP expression.  When transformant expression was compared to the 
protein recovered from a non-transformed C. reinhardtii WT strain, the NP protein 
expression detected was significant, p<0.001.  The level of significance 
demonstrating expression of IV NP in the microalga, C. reinhardtii.   
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Conclusion 
 
The World Health Organization (WHO), the National Institutes of Health, and 
UNESCO, have highlighted the need for alternative low-cost vaccines to promote 
vaccination programs in the world's poorest regions. They especially emphasized the 
requirement for heat-stable vaccines to minimize the considerable expense in 
maintaining the cold-chain during production and distribution, and needle-free 
formulations to eliminate the risk of opportunistic contamination as well the need for 
qualified personnel. To construct an alternative Influenza vaccine to meet these 
requirements would be a highly advantageous since Influenza (IV) is one of the most 
significant diseases worldwide, being implicated in 4 major pandemics and the 
causative agent of ongoing yearly epidemics resulting in significant morbidity and 
mortality. 
 
We engineered the chloroplast genome of C. reinhardtii to express the IV 
nucleoprotein using an NP transgene under the control of chloroplast-specific 
regulatory sequences promoters and terminators, where a large region of the tscA 
gene was used for integration into the chloroplast genome via homological 
recombination. Integration and expression of the NP transgene were confirmed 
phenotypically by antibiotic streptomycin selection and using a set of molecular 
biology techniques such as PCR, RT PCR, DNA sequencing and ELISA. 
 
For the future 
It is considered: 
• NP expression for all C. reinhardtii transformants be studied further, and 
include the effect of protein purification and quantification to select the most 
expressive of the 7 transformants.   
• The best method for oral route delivery of vaccine candidate; encapsulation or 
a preformed dried state to ensure a measured and controlled dosage. 
• A mouse and poultry animal trial to confirm immunogenicity, safety and 
efficacy of vaccine candidate. 
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